Congenital Adrenal Hyperplasia

Mendelian MONDO:0018479 Pathograph 16 Steroid Inherited Metabolic Disorder Chronic Primary Adrenal Insufficiency

Congenital adrenal hyperplasia is a genetically heterogeneous group of adrenal steroidogenesis disorders. The curated scope here emphasizes 21-hydroxylase deficiency because Falcon research identified it as the overwhelmingly predominant form, while preserving subtype framing for the major rarer CAH enzyme defects.

Ask OpenScientist

Ask a research question about Congenital Adrenal Hyperplasia. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
6
Pathophys.
11
Phenotypes
16
Pathograph
5
Genes
4
Treatments
8
Subtypes
2
Trials
18
References
1
Deep Research
👪

Inheritance

1
Autosomal Recessive HP:0000007
CAH due to 21-hydroxylase deficiency and the other classic steroidogenic enzyme defects is inherited in an autosomal recessive pattern.
autosomal recessive inheritance
Show evidence (1 reference)
PMID:39911519 SUPPORT Human Clinical
"Of all congenital adrenal hyperplasia (CAH), 95% to 99% is 21-hydroxylase deficiency (21OHD), an autosomal recessive disease."
This review explicitly identifies the predominant 21-OHD form as autosomal recessive and frames its contribution to all CAH.
◆

Subtypes

8
Classic 21-hydroxylase deficiency MONDO:0008728
Classic CYP21A2-related CAH with severe 21-hydroxylase deficiency; includes salt-wasting and simple-virilizing clinical forms.
Classic salt-wasting 21-hydroxylase deficiency MONDO:0017839
Severe classic 21-hydroxylase deficiency with cortisol and aldosterone deficiency, neonatal salt-wasting risk, and adrenal androgen excess.
Classic simple-virilizing 21-hydroxylase deficiency MONDO:0017840
Classic 21-hydroxylase deficiency with cortisol deficiency and adrenal androgen excess but less prominent mineralocorticoid deficiency.
Nonclassic congenital adrenal hyperplasia MONDO:0023601
Later-onset, milder 21-hydroxylase deficiency usually presenting with hyperandrogenism rather than neonatal adrenal crisis.
11 beta-hydroxylase deficiency MONDO:0008729
CAH caused by CYP11B1 deficiency, with cortisol deficiency, adrenal androgen excess, and accumulation of mineralocorticoid precursors.
17 alpha-hydroxylase/17,20-lyase deficiency MONDO:0008730
CAH caused by CYP17A1 deficiency, impairing cortisol and sex-steroid synthesis with relative mineralocorticoid precursor excess.
3 beta-hydroxysteroid dehydrogenase deficiency MONDO:0008727
CAH caused by HSD3B2 deficiency, disrupting glucocorticoid, mineralocorticoid, and sex-steroid synthesis.
Lipoid congenital adrenal hyperplasia MONDO:0008725
Severe STAR-related steroidogenesis disorder impairing cholesterol delivery for adrenal and gonadal steroid hormone synthesis.
⚙

Pathophysiology

6
CYP21A2 21-Hydroxylase Deficiency
Loss of CYP21A2 21-hydroxylase activity impairs adrenal steroidogenesis, reducing cortisol and, in severe classic disease, aldosterone production.
adrenal cortical cell link
CYP21A2 link
steroid biosynthetic process link ↓ DECREASED C21-steroid hormone biosynthetic process link ↓ DECREASED
Downstream
Cortisol and Aldosterone Deficiency Impaired 21-hydroxylation reduces normal glucocorticoid and, in severe classic disease, mineralocorticoid production.
Show evidence (1 reference)
PMID:39911519 SUPPORT Human Clinical
"21OHD is due to an insufficiency of 21-hydroxylase enzyme, which is encoded by the CYP21A2 gene and involved in cortisol and aldosterone production."
Establishes that CYP21A2-encoded 21-hydroxylase is required for cortisol and aldosterone production.
CYP11B1 11-Beta-Hydroxylase Deficiency
CYP11B1 pathogenic variants reduce steroid 11 beta-hydroxylase function, producing a rare CAH subtype with aberrant sex-steroid production, virilization, and mineralocorticoid precursor-mediated hypertension.
adrenal cortical cell link
CYP11B1 link
steroid biosynthetic process link ⚠ ABNORMAL
steroid 11-beta-monooxygenase activity link ↓ DECREASED
Downstream
ACTH-Driven Adrenal Hyperplasia and Androgen Excess Blocked 11 beta-hydroxylase disrupts cortisol synthesis and steroid flux, promoting adrenal stimulation and androgen excess.
Hypertension Mineralocorticoid precursor accumulation in 11 beta-hydroxylase deficiency promotes hypertension.
Show evidence (2 references)
PMID:28228528 SUPPORT Human Clinical
"Congenital adrenal hyperplasia (CAH), resulting from mutations in CYP11B1, a gene encoding 11β-hydroxylase, represents a rare autosomal recessive Mendelian disorder of aberrant sex steroid production."
Supports CYP11B1 loss as a steroidogenic enzyme-deficiency mechanism in the 11B-OHD subtype.
PMID:28228528 SUPPORT Human Clinical
"Clinically, affected female newborns are profoundly virilized (Prader score of 4/5), and both genders display significantly advanced bone ages and are oftentimes hypertensive."
Links the 11 beta-hydroxylase deficiency mechanism to virilization and hypertension in the human cohort.
CYP17A1 17-Hydroxylase/17,20-Lyase Deficiency
CYP17A1 pathogenic variants reduce steroid 17 alpha-hydroxylase/17,20-lyase activity, causing a rare CAH subtype characterized by cortisol deficiency, sex-steroid deficiency, and mineralocorticoid excess.
adrenal cortical cell link
CYP17A1 link
steroid biosynthetic process link ⚠ ABNORMAL
steroid 17-alpha-monooxygenase activity link ↓ DECREASED
Downstream
Adrenal Insufficiency Cortisol deficiency from impaired CYP17A1 steroidogenesis contributes to adrenal insufficiency.
Hypertension Mineralocorticoid excess from impaired CYP17A1 steroidogenesis promotes hypertension.
Show evidence (1 reference)
PMID:34524979 SUPPORT Human Clinical
"17α-Hydroxylase/17,20-lyase deficiency (17OHD) caused by mutations in the CYP17A1 gene is a rare form of congenital adrenal hyperplasia typically characterised by cortisol deficiency, mineralocorticoid excess and sex steroid deficiency."
Supports CYP17A1 loss as a rare CAH mechanism with the expected cortisol, mineralocorticoid, and sex-steroid pattern.
Cortisol and Aldosterone Deficiency
Deficient cortisol removes negative feedback on ACTH secretion; aldosterone deficiency in salt-wasting disease causes electrolyte and volume instability.
adrenal cortical cell link
steroid biosynthetic process link ↓ DECREASED
Downstream
ACTH-Driven Adrenal Hyperplasia and Androgen Excess Reduced cortisol feedback increases adrenal stimulation and contributes to androgen precursor shunting.
Show evidence (1 reference)
PMID:37176569 SUPPORT Human Clinical
"CAH is characterized by the overproduction of androgen, along with variable degrees of cortisol and aldosterone deficiency."
Summarizes the core hormonal abnormalities linking cortisol and aldosterone deficiency with androgen excess.
ACTH-Driven Adrenal Hyperplasia and Androgen Excess
Persistent adrenal stimulation and blocked steroidogenic flux promote adrenal cortical hyperplasia and excess androgen production.
adrenal cortical cell link
steroid biosynthetic process link ⚠ ABNORMAL
Downstream
Prenatal and Postnatal Hyperandrogenism Excess adrenal androgens produce virilization at birth in some 46,XX infants and later hyperandrogenic manifestations.
Show evidence (1 reference)
PMID:38791102 SUPPORT Model Organism
"Congenital Adrenal Hyperplasia (CAH) is an autosomal recessive disorder impairing cortisol synthesis due to reduced enzymatic activity. This leads to persistent adrenocortical overstimulation and the accumulation of precursors before the blocked enzymatic step."
The humanized mouse-model abstract summarizes how reduced enzyme activity drives persistent adrenal stimulation and precursor accumulation.
Prenatal and Postnatal Hyperandrogenism
Excess adrenal androgen exposure causes prenatal genital virilization and later hyperandrogenic features such as hirsutism, acne, menstrual irregularity, and infertility.
adrenal cortical cell link
steroid biosynthetic process link ↑ INCREASED
Show evidence (1 reference)
PMID:37176569 SUPPORT Human Clinical
"Non-classic CAH, a milder form of CAH, is usually manifested later in life and is a common differential diagnosis of Polycystic Ovary Syndrome and should be actively evaluated during initial studies of clinical or biochemical hyperandrogenism."
Supports late-presenting hyperandrogenism in nonclassic CAH and its clinical overlap with PCOS.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Congenital Adrenal Hyperplasia Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

11
Cardiovascular 1
Hypertension Hypertension (HP:0000822)
Show evidence (3 references)
PMID:36857009 SUPPORT Human Clinical
"Information collected included current therapy and surveillance practice with a particular focus on osteoporosis/osteopaenia, hyperlipidaemia, type 2 diabetes/hyperinsulinaemia, hypertension, CV disease, obesity."
The adult specialist-centre survey explicitly includes hypertension among monitored CAH comorbidity domains.
PMID:28228528 SUPPORT Human Clinical
"Clinically, affected female newborns are profoundly virilized (Prader score of 4/5), and both genders display significantly advanced bone ages and are oftentimes hypertensive."
Directly supports hypertension as a manifestation of CYP11B1-related 11 beta-hydroxylase deficiency CAH.
PMID:34524979 SUPPORT Human Clinical
"17α-Hydroxylase/17,20-lyase deficiency (17OHD) caused by mutations in the CYP17A1 gene is a rare form of congenital adrenal hyperplasia typically characterised by cortisol deficiency, mineralocorticoid excess and sex steroid deficiency."
Supports mineralocorticoid excess in CYP17A1-related CAH, the endocrine mechanism underlying hypertension in this subtype.
Endocrine 2
Adrenal Insufficiency Adrenal insufficiency (HP:0000846)
Show evidence (2 references)
PMID:37176569 SUPPORT Human Clinical
"The age at diagnosis can provide some information about underlying mutations, with those diagnosed at birth/early infancy more likely to have severe enzymatic defects, which may include adrenal insufficiency, sexual development disorders, short stature in adulthood, hirsutism, and a higher risk..."
Identifies adrenal insufficiency among severe early-diagnosed CAH manifestations.
PMID:34524979 SUPPORT Human Clinical
"17α-Hydroxylase/17,20-lyase deficiency (17OHD) caused by mutations in the CYP17A1 gene is a rare form of congenital adrenal hyperplasia typically characterised by cortisol deficiency, mineralocorticoid excess and sex steroid deficiency."
Supports cortisol deficiency, the adrenal-insufficiency component, in CYP17A1-related CAH.
Type 2 Diabetes or Hyperinsulinemia Type II diabetes mellitus (HP:0005978)
Show evidence (1 reference)
PMID:36857009 SUPPORT Human Clinical
"Of 73, the patients who were treated for osteoporosis/osteopaenia, hyperlipidaemia, type 2 diabetes/hyperinsulinaemia, hypertension, CV disease, obesity were 43 (59%), 17 (23%), 16 (22%), 10 (14%), 8 (11), 3 (4%) respectively."
Directly reports treated type 2 diabetes/hyperinsulinemia among adult CAH comorbidity cases.
Genitourinary 2
Irregular Menstruation Irregular menstruation (HP:0000858)
Show evidence (1 reference)
PMID:37176569 PARTIAL Human Clinical
"Non-classic CAH, a milder form of CAH, is usually manifested later in life and is a common differential diagnosis of Polycystic Ovary Syndrome and should be actively evaluated during initial studies of clinical or biochemical hyperandrogenism."
The snippet supports PCOS-like hyperandrogenism; menstrual irregularity is represented as one common clinical component of that syndrome-level presentation.
Infertility Infertility (HP:0000789)
Show evidence (1 reference)
PMID:37176569 SUPPORT Human Clinical
"The age at diagnosis can provide some information about underlying mutations, with those diagnosed at birth/early infancy more likely to have severe enzymatic defects, which may include adrenal insufficiency, sexual development disorders, short stature in adulthood, hirsutism, and a higher risk..."
Directly lists infertility among severe CAH risks.
Integument 1
Hirsutism Hirsutism (HP:0001007)
Show evidence (1 reference)
PMID:37176569 SUPPORT Human Clinical
"The age at diagnosis can provide some information about underlying mutations, with those diagnosed at birth/early infancy more likely to have severe enzymatic defects, which may include adrenal insufficiency, sexual development disorders, short stature in adulthood, hirsutism, and a higher risk..."
Directly lists hirsutism among CAH manifestations.
Metabolism 1
Salt-Wasting Electrolyte Crisis Hyponatremia (HP:0002902)
Onset: NEONATAL
Show evidence (1 reference)
PMID:37176569 SUPPORT Human Clinical
"CAH is characterized by the overproduction of androgen, along with variable degrees of cortisol and aldosterone deficiency."
Aldosterone deficiency is the upstream hormonal defect underlying salt-wasting electrolyte crisis in severe CAH.
Musculoskeletal 1
Osteoporosis or Osteopenia Osteoporosis (HP:0000939)
Show evidence (1 reference)
PMID:36857009 SUPPORT Human Clinical
"Of 73, the patients who were treated for osteoporosis/osteopaenia, hyperlipidaemia, type 2 diabetes/hyperinsulinaemia, hypertension, CV disease, obesity were 43 (59%), 17 (23%), 16 (22%), 10 (14%), 8 (11), 3 (4%) respectively."
Directly reports osteoporosis/osteopaenia treatment among adults with classic 21-hydroxylase deficiency CAH treated for comorbidities.
Growth 1
Short Stature Short stature (HP:0004322)
Show evidence (1 reference)
PMID:37176569 SUPPORT Human Clinical
"The age at diagnosis can provide some information about underlying mutations, with those diagnosed at birth/early infancy more likely to have severe enzymatic defects, which may include adrenal insufficiency, sexual development disorders, short stature in adulthood, hirsutism, and a higher risk..."
Directly identifies short stature in adulthood among severe CAH manifestations.
Other 2
Ambiguous Genitalia and 46,XX Virilization Ambiguous genitalia (HP:0000062)
Onset: CONGENITAL
Show evidence (1 reference)
PMID:37176569 SUPPORT Human Clinical
"The age at diagnosis can provide some information about underlying mutations, with those diagnosed at birth/early infancy more likely to have severe enzymatic defects, which may include adrenal insufficiency, sexual development disorders, short stature in adulthood, hirsutism, and a higher risk..."
Supports early sexual-development manifestations in severe CAH.
Testicular Adrenal Rest Tumors
Show evidence (1 reference)
PMID:40921717 SUPPORT Human Clinical
"Testicular adrenal rest tumors (TART) frequently develop and are the most common cause of male infertility in classic congenital adrenal hyperplasia (CAH)."
Directly identifies TART as a frequent manifestation in classic CAH and links it to male infertility.
🧬

Genetic Associations

5
CYP21A2 pathogenic variants (Causative)
Show evidence (1 reference)
PMID:39911519 SUPPORT Human Clinical
"21OHD is due to an insufficiency of 21-hydroxylase enzyme, which is encoded by the CYP21A2 gene and involved in cortisol and aldosterone production."
Directly links CYP21A2 to 21-hydroxylase deficiency.
CYP11B1 pathogenic variants (Causative)
Show evidence (1 reference)
PMID:28228528 SUPPORT Human Clinical
"Congenital adrenal hyperplasia (CAH), resulting from mutations in CYP11B1, a gene encoding 11β-hydroxylase, represents a rare autosomal recessive Mendelian disorder of aberrant sex steroid production."
Human cohort and structural study supports CYP11B1 variants as the disease-causing basis of the 11 beta-hydroxylase deficiency subtype.
CYP17A1 pathogenic variants (Causative)
Show evidence (1 reference)
PMID:34524979 SUPPORT Human Clinical
"17α-Hydroxylase/17,20-lyase deficiency (17OHD) caused by mutations in the CYP17A1 gene is a rare form of congenital adrenal hyperplasia typically characterised by cortisol deficiency, mineralocorticoid excess and sex steroid deficiency."
Human case-series evidence directly links CYP17A1 mutations to the 17OHD CAH subtype and its steroid hormone pattern.
HSD3B2 pathogenic variants (Causative)
STAR pathogenic variants (Causative)
💊

Treatments

4
Glucocorticoid replacement
Action: Pharmacotherapy NCIT:C15986
Agent: therapeutic hydrocortisone ↗
Glucocorticoid therapy replaces deficient cortisol and suppresses excess ACTH-driven adrenal androgen production; treatment must balance androgen control against glucocorticoid-related complications.
Mechanism Target:
RESTORES Cortisol and Aldosterone Deficiency — Glucocorticoid replacement restores deficient cortisol action.
INHIBITS ACTH-Driven Adrenal Hyperplasia and Androgen Excess — Adequate glucocorticoid replacement suppresses ACTH-driven adrenal androgen overproduction.
Show evidence (1 reference)
PMID:38828955 SUPPORT Human Clinical
"Adrenal insufficiency in patients with classic 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH) is treated with glucocorticoid replacement therapy."
Directly supports glucocorticoid replacement as standard CAH therapy.
Mineralocorticoid replacement
Action: Pharmacotherapy NCIT:C15986
Agent: fludrocortisone ↗
Fludrocortisone replaces mineralocorticoid activity in salt-wasting CAH and is used with glucocorticoids in many adults with classic disease.
Mechanism Target:
RESTORES Cortisol and Aldosterone Deficiency — Fludrocortisone replaces deficient mineralocorticoid action.
Target Phenotypes: hyponatremia ↗
Show evidence (1 reference)
PMID:36857009 SUPPORT Human Clinical
"Of these, 126 (52%) were females and 174 (71%) received fludrocortisone in addition to glucocorticoids."
Documents frequent combined fludrocortisone and glucocorticoid treatment in adults with classic 21-hydroxylase deficiency CAH.
Crinecerfont adjunct therapy
Action: Pharmacotherapy NCIT:C15986
Agent: crinecerfont ↗
Crinecerfont is an oral corticotropin-releasing factor type 1 receptor antagonist that reduces ACTH-driven androgen excess and enables lower glucocorticoid doses in classic CAH.
Mechanism Target:
INHIBITS ACTH-Driven Adrenal Hyperplasia and Androgen Excess — CRF1 receptor antagonism lowers ACTH drive and helps reduce adrenal androgen excess.
Show evidence (2 references)
PMID:38828955 SUPPORT Human Clinical
"Crinecerfont, an oral corticotropin-releasing factor type 1 receptor antagonist, lowered androstenedione levels in phase 2 trials involving patients with CAH."
Identifies the mechanism and prior androgen-lowering evidence for crinecerfont in CAH.
PMID:38828955 SUPPORT Human Clinical
"Among patients with CAH, the use of crinecerfont resulted in a greater decrease from baseline in the mean daily glucocorticoid dose, including a reduction to the physiologic range, than placebo following evaluation of adrenal androgen levels."
Phase 3 evidence supports a glucocorticoid-sparing benefit while monitoring adrenal androgen control.
CYP21A2 gene therapy
Action: gene therapy MAXO:0001001
AAV-mediated CYP21A2 gene therapy is investigational and is designed to restore adrenal steroidogenesis upstream of hormone deficiency and androgen shunting.
Mechanism Target:
RESTORES CYP21A2 21-Hydroxylase Deficiency — CYP21A2 delivery aims to restore the deficient steroidogenic enzyme step.
Show evidence (1 reference)
PMID:36982440 PARTIAL Other
"Congenital adrenal hyperplasia (CAH) is an example of such a potentially treatable monogenic disease."
Supports gene therapy as a plausible investigational strategy while not establishing clinical efficacy.
🔬

Biochemical Markers

2
Elevated 17-hydroxyprogesterone
Show evidence (1 reference)
PMID:28938470 SUPPORT Model Organism
"Furthermore, Cyp21a2-deficient larvae had a typical steroid profile, with reduced concentrations of cortisol and increased concentrations of 17-hydroxyprogesterone and 21-deoxycortisol."
The zebrafish 21OHD model recapitulates the expected steroid precursor accumulation pattern.
Reduced Cortisol
Show evidence (1 reference)
PMID:38791102 SUPPORT Model Organism
"Mutant mice showed hyperplastic adrenals and exhibited reduced levels of corticosterone and 11-deoxycorticosterone and an increase in progesterone."
In the humanized mouse model, reduced glucocorticoid-pathway products and increased precursors support the blocked steroidogenesis model.
🔬

Clinical Trials

2
NCT04490915 PHASE_III ACTIVE_NOT_RECRUITING
Phase 3 trial of crinecerfont versus placebo in adults with classic CAH due to 21-hydroxylase deficiency, followed by open-label treatment.
Show evidence (1 reference)
clinicaltrials:NCT04490915 SUPPORT Human Clinical
"This is a Phase 3 study to evaluate the efficacy, safety, and tolerability of crinecerfont versus placebo administered for 24 weeks in approximately 165 adult participants with classic CAH due to 21-hydroxylase deficiency."
The trial record directly describes the crinecerfont CAH phase 3 study.
NCT04783181 PHASE_I ACTIVE_NOT_RECRUITING
Phase 1/2 first-in-human AAV5-based BBP-631 CYP21A2 gene therapy study for adults with classic CAH.
Show evidence (1 reference)
clinicaltrials:NCT04783181 SUPPORT Human Clinical
"This study is designed to evaluate the safety, tolerability, and efficacy of AAV5 based BBP-631 in adult participants diagnosed with classic congenital adrenal hyperplasia."
The trial record directly describes an AAV5 BBP-631 gene therapy study in classic CAH.
{ }

Source YAML

click to show 
name: Congenital Adrenal Hyperplasia
creation_date: "2026-05-07T12:55:39Z"
updated_date: "2026-05-09T20:20:45Z"
category: Mendelian
synonyms:
- CAH
- adrenal hyperplasia, congenital
- adrenogenital syndrome
description: >-
  Congenital adrenal hyperplasia is a genetically heterogeneous group of
  adrenal steroidogenesis disorders. The curated scope here emphasizes
  21-hydroxylase deficiency because Falcon research identified it as the
  overwhelmingly predominant form, while preserving subtype framing for the
  major rarer CAH enzyme defects.
disease_term:
  preferred_term: congenital adrenal hyperplasia
  term:
    id: MONDO:0018479
    label: congenital adrenal hyperplasia
parents:
- Steroid Inherited Metabolic Disorder
- Chronic Primary Adrenal Insufficiency
has_subtypes:
- name: Classic 21-OHD
  display_name: Classic 21-hydroxylase deficiency
  description: >-
    Classic CYP21A2-related CAH with severe 21-hydroxylase deficiency; includes
    salt-wasting and simple-virilizing clinical forms.
  subtype_term:
    preferred_term: classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency
    term:
      id: MONDO:0008728
      label: classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency
- name: Salt-Wasting 21-OHD
  display_name: Classic salt-wasting 21-hydroxylase deficiency
  description: >-
    Severe classic 21-hydroxylase deficiency with cortisol and aldosterone
    deficiency, neonatal salt-wasting risk, and adrenal androgen excess.
  subtype_term:
    preferred_term: classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, salt wasting form
    term:
      id: MONDO:0017839
      label: classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, salt wasting form
- name: Simple-Virilizing 21-OHD
  display_name: Classic simple-virilizing 21-hydroxylase deficiency
  description: >-
    Classic 21-hydroxylase deficiency with cortisol deficiency and adrenal
    androgen excess but less prominent mineralocorticoid deficiency.
  subtype_term:
    preferred_term: classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, simple virilizing form
    term:
      id: MONDO:0017840
      label: classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, simple virilizing form
- name: Nonclassic 21-OHD
  display_name: Nonclassic congenital adrenal hyperplasia
  description: >-
    Later-onset, milder 21-hydroxylase deficiency usually presenting with
    hyperandrogenism rather than neonatal adrenal crisis.
  subtype_term:
    preferred_term: non-classic congenital adrenal hyperplasia
    term:
      id: MONDO:0023601
      label: non-classic congenital adrenal hyperplasia
- name: 11B-OHD
  display_name: 11 beta-hydroxylase deficiency
  description: >-
    CAH caused by CYP11B1 deficiency, with cortisol deficiency, adrenal androgen
    excess, and accumulation of mineralocorticoid precursors.
  subtype_term:
    preferred_term: congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency
    term:
      id: MONDO:0008729
      label: congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency
- name: 17A-OHD
  display_name: 17 alpha-hydroxylase/17,20-lyase deficiency
  description: >-
    CAH caused by CYP17A1 deficiency, impairing cortisol and sex-steroid
    synthesis with relative mineralocorticoid precursor excess.
  subtype_term:
    preferred_term: congenital adrenal hyperplasia due to 17-alpha-hydroxylase deficiency
    term:
      id: MONDO:0008730
      label: congenital adrenal hyperplasia due to 17-alpha-hydroxylase deficiency
- name: 3B-HSD
  display_name: 3 beta-hydroxysteroid dehydrogenase deficiency
  description: >-
    CAH caused by HSD3B2 deficiency, disrupting glucocorticoid,
    mineralocorticoid, and sex-steroid synthesis.
  subtype_term:
    preferred_term: congenital adrenal hyperplasia due to 3-beta-hydroxysteroid dehydrogenase deficiency
    term:
      id: MONDO:0008727
      label: congenital adrenal hyperplasia due to 3-beta-hydroxysteroid dehydrogenase deficiency
- name: Lipoid CAH
  display_name: Lipoid congenital adrenal hyperplasia
  description: >-
    Severe STAR-related steroidogenesis disorder impairing cholesterol delivery
    for adrenal and gonadal steroid hormone synthesis.
  subtype_term:
    preferred_term: congenital lipoid adrenal hyperplasia due to STAR deficiency
    term:
      id: MONDO:0008725
      label: congenital lipoid adrenal hyperplasia due to STAR deficency
inheritance:
- name: Autosomal Recessive
  inheritance_term:
    preferred_term: autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >-
    CAH due to 21-hydroxylase deficiency and the other classic steroidogenic
    enzyme defects is inherited in an autosomal recessive pattern.
  evidence:
  - reference: PMID:39911519
    reference_title: "Genetics in Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency and Clinical Implications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Of all congenital adrenal hyperplasia (CAH), 95% to 99% is
      21-hydroxylase deficiency (21OHD), an autosomal recessive disease.
    explanation: >-
      This review explicitly identifies the predominant 21-OHD form as
      autosomal recessive and frames its contribution to all CAH.
genetic:
- name: CYP21A2 pathogenic variants
  gene_term:
    preferred_term: CYP21A2
    term:
      id: hgnc:2600
      label: CYP21A2
  association: Causative
  subtype: Classic 21-OHD
  features: >-
    CYP21A2 variants cause 21-hydroxylase deficiency, producing the dominant
    CAH subtype and a phenotype spectrum from classic salt-wasting disease to
    nonclassic hyperandrogenism.
  evidence:
  - reference: PMID:39911519
    reference_title: "Genetics in Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency and Clinical Implications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      21OHD is due to an insufficiency of 21-hydroxylase enzyme, which is
      encoded by the CYP21A2 gene and involved in cortisol and aldosterone
      production.
    explanation: Directly links CYP21A2 to 21-hydroxylase deficiency.
- name: CYP11B1 pathogenic variants
  gene_term:
    preferred_term: CYP11B1
    term:
      id: hgnc:2591
      label: CYP11B1
  association: Causative
  subtype: 11B-OHD
  features: >-
    CYP11B1 variants cause 11 beta-hydroxylase deficiency CAH.
  evidence:
  - reference: PMID:28228528
    reference_title: "Clinical, genetic, and structural basis of congenital adrenal hyperplasia due to 11β-hydroxylase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Congenital adrenal hyperplasia (CAH), resulting from mutations in CYP11B1,
      a gene encoding 11β-hydroxylase, represents a rare autosomal recessive
      Mendelian disorder of aberrant sex steroid production.
    explanation: >-
      Human cohort and structural study supports CYP11B1 variants as the
      disease-causing basis of the 11 beta-hydroxylase deficiency subtype.
- name: CYP17A1 pathogenic variants
  gene_term:
    preferred_term: CYP17A1
    term:
      id: hgnc:2593
      label: CYP17A1
  association: Causative
  subtype: 17A-OHD
  features: >-
    CYP17A1 variants cause 17 alpha-hydroxylase/17,20-lyase deficiency CAH.
  evidence:
  - reference: PMID:34524979
    reference_title: "The broad phenotypic spectrum of 17α-hydroxylase/17,20-lyase (CYP17A1) deficiency: a case series."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      17α-Hydroxylase/17,20-lyase deficiency (17OHD) caused by mutations in
      the CYP17A1 gene is a rare form of congenital adrenal hyperplasia
      typically characterised by cortisol deficiency, mineralocorticoid excess
      and sex steroid deficiency.
    explanation: >-
      Human case-series evidence directly links CYP17A1 mutations to the
      17OHD CAH subtype and its steroid hormone pattern.
- name: HSD3B2 pathogenic variants
  gene_term:
    preferred_term: HSD3B2
    term:
      id: hgnc:5218
      label: HSD3B2
  association: Causative
  subtype: 3B-HSD
  features: >-
    HSD3B2 variants cause 3 beta-hydroxysteroid dehydrogenase deficiency CAH.
- name: STAR pathogenic variants
  gene_term:
    preferred_term: STAR
    term:
      id: hgnc:11359
      label: STAR
  association: Causative
  subtype: Lipoid CAH
  features: >-
    STAR variants cause lipoid congenital adrenal hyperplasia by impairing
    cholesterol delivery for steroidogenesis.
pathophysiology:
- name: CYP21A2 21-Hydroxylase Deficiency
  description: >-
    Loss of CYP21A2 21-hydroxylase activity impairs adrenal steroidogenesis,
    reducing cortisol and, in severe classic disease, aldosterone production.
  genes:
  - preferred_term: CYP21A2
    term:
      id: hgnc:2600
      label: CYP21A2
  cell_types:
  - preferred_term: adrenal cortical cell
    term:
      id: CL:0002097
      label: cortical cell of adrenal gland
  biological_processes:
  - preferred_term: steroid biosynthetic process
    term:
      id: GO:0006694
      label: steroid biosynthetic process
    modifier: DECREASED
  - preferred_term: C21-steroid hormone biosynthetic process
    term:
      id: GO:0006700
      label: C21-steroid hormone biosynthetic process
    modifier: DECREASED
  evidence:
  - reference: PMID:39911519
    reference_title: "Genetics in Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency and Clinical Implications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      21OHD is due to an insufficiency of 21-hydroxylase enzyme, which is
      encoded by the CYP21A2 gene and involved in cortisol and aldosterone
      production.
    explanation: >-
      Establishes that CYP21A2-encoded 21-hydroxylase is required for cortisol
      and aldosterone production.
  downstream:
  - target: Cortisol and Aldosterone Deficiency
    description: >-
      Impaired 21-hydroxylation reduces normal glucocorticoid and, in severe
      classic disease, mineralocorticoid production.
- name: CYP11B1 11-Beta-Hydroxylase Deficiency
  description: >-
    CYP11B1 pathogenic variants reduce steroid 11 beta-hydroxylase function,
    producing a rare CAH subtype with aberrant sex-steroid production,
    virilization, and mineralocorticoid precursor-mediated hypertension.
  genes:
  - preferred_term: CYP11B1
    term:
      id: hgnc:2591
      label: CYP11B1
  cell_types:
  - preferred_term: adrenal cortical cell
    term:
      id: CL:0002097
      label: cortical cell of adrenal gland
  molecular_functions:
  - preferred_term: steroid 11-beta-monooxygenase activity
    term:
      id: GO:0004507
      label: steroid 11-beta-monooxygenase activity
    modifier: DECREASED
  biological_processes:
  - preferred_term: steroid biosynthetic process
    term:
      id: GO:0006694
      label: steroid biosynthetic process
    modifier: ABNORMAL
  evidence:
  - reference: PMID:28228528
    reference_title: "Clinical, genetic, and structural basis of congenital adrenal hyperplasia due to 11β-hydroxylase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Congenital adrenal hyperplasia (CAH), resulting from mutations in CYP11B1,
      a gene encoding 11β-hydroxylase, represents a rare autosomal recessive
      Mendelian disorder of aberrant sex steroid production.
    explanation: >-
      Supports CYP11B1 loss as a steroidogenic enzyme-deficiency mechanism in
      the 11B-OHD subtype.
  - reference: PMID:28228528
    reference_title: "Clinical, genetic, and structural basis of congenital adrenal hyperplasia due to 11β-hydroxylase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinically, affected female newborns are profoundly virilized (Prader
      score of 4/5), and both genders display significantly advanced bone ages
      and are oftentimes hypertensive.
    explanation: >-
      Links the 11 beta-hydroxylase deficiency mechanism to virilization and
      hypertension in the human cohort.
  downstream:
  - target: ACTH-Driven Adrenal Hyperplasia and Androgen Excess
    description: >-
      Blocked 11 beta-hydroxylase disrupts cortisol synthesis and steroid flux,
      promoting adrenal stimulation and androgen excess.
  - target: Hypertension
    description: >-
      Mineralocorticoid precursor accumulation in 11 beta-hydroxylase deficiency
      promotes hypertension.
- name: CYP17A1 17-Hydroxylase/17,20-Lyase Deficiency
  description: >-
    CYP17A1 pathogenic variants reduce steroid 17 alpha-hydroxylase/17,20-lyase
    activity, causing a rare CAH subtype characterized by cortisol deficiency,
    sex-steroid deficiency, and mineralocorticoid excess.
  genes:
  - preferred_term: CYP17A1
    term:
      id: hgnc:2593
      label: CYP17A1
  cell_types:
  - preferred_term: adrenal cortical cell
    term:
      id: CL:0002097
      label: cortical cell of adrenal gland
  molecular_functions:
  - preferred_term: steroid 17-alpha-monooxygenase activity
    term:
      id: GO:0004508
      label: steroid 17-alpha-monooxygenase activity
    modifier: DECREASED
  biological_processes:
  - preferred_term: steroid biosynthetic process
    term:
      id: GO:0006694
      label: steroid biosynthetic process
    modifier: ABNORMAL
  evidence:
  - reference: PMID:34524979
    reference_title: "The broad phenotypic spectrum of 17α-hydroxylase/17,20-lyase (CYP17A1) deficiency: a case series."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      17α-Hydroxylase/17,20-lyase deficiency (17OHD) caused by mutations in
      the CYP17A1 gene is a rare form of congenital adrenal hyperplasia
      typically characterised by cortisol deficiency, mineralocorticoid excess
      and sex steroid deficiency.
    explanation: >-
      Supports CYP17A1 loss as a rare CAH mechanism with the expected cortisol,
      mineralocorticoid, and sex-steroid pattern.
  downstream:
  - target: Adrenal Insufficiency
    description: >-
      Cortisol deficiency from impaired CYP17A1 steroidogenesis contributes to
      adrenal insufficiency.
  - target: Hypertension
    description: >-
      Mineralocorticoid excess from impaired CYP17A1 steroidogenesis promotes
      hypertension.
- name: Cortisol and Aldosterone Deficiency
  description: >-
    Deficient cortisol removes negative feedback on ACTH secretion; aldosterone
    deficiency in salt-wasting disease causes electrolyte and volume
    instability.
  cell_types:
  - preferred_term: adrenal cortical cell
    term:
      id: CL:0002097
      label: cortical cell of adrenal gland
  chemical_entities:
  - preferred_term: cortisol
    term:
      id: CHEBI:17650
      label: cortisol
  - preferred_term: aldosterone
    term:
      id: CHEBI:27584
      label: aldosterone
  biological_processes:
  - preferred_term: steroid biosynthetic process
    term:
      id: GO:0006694
      label: steroid biosynthetic process
    modifier: DECREASED
  evidence:
  - reference: PMID:37176569
    reference_title: "Clinical Update on Congenital Adrenal Hyperplasia: Recommendations from a Multidisciplinary Adrenal Program."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      CAH is characterized by the overproduction of androgen, along with
      variable degrees of cortisol and aldosterone deficiency.
    explanation: >-
      Summarizes the core hormonal abnormalities linking cortisol and
      aldosterone deficiency with androgen excess.
  downstream:
  - target: ACTH-Driven Adrenal Hyperplasia and Androgen Excess
    description: >-
      Reduced cortisol feedback increases adrenal stimulation and contributes
      to androgen precursor shunting.
- name: ACTH-Driven Adrenal Hyperplasia and Androgen Excess
  description: >-
    Persistent adrenal stimulation and blocked steroidogenic flux promote
    adrenal cortical hyperplasia and excess androgen production.
  cell_types:
  - preferred_term: adrenal cortical cell
    term:
      id: CL:0002097
      label: cortical cell of adrenal gland
  biological_processes:
  - preferred_term: steroid biosynthetic process
    term:
      id: GO:0006694
      label: steroid biosynthetic process
    modifier: ABNORMAL
  evidence:
  - reference: PMID:38791102
    reference_title: "A Humanized and Viable Animal Model for Congenital Adrenal Hyperplasia-CYP21A2-R484Q Mutant Mouse."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Congenital Adrenal Hyperplasia (CAH) is an autosomal recessive disorder
      impairing cortisol synthesis due to reduced enzymatic activity. This leads
      to persistent adrenocortical overstimulation and the accumulation of
      precursors before the blocked enzymatic step.
    explanation: >-
      The humanized mouse-model abstract summarizes how reduced enzyme activity
      drives persistent adrenal stimulation and precursor accumulation.
  downstream:
  - target: Prenatal and Postnatal Hyperandrogenism
    description: >-
      Excess adrenal androgens produce virilization at birth in some 46,XX
      infants and later hyperandrogenic manifestations.
- name: Prenatal and Postnatal Hyperandrogenism
  description: >-
    Excess adrenal androgen exposure causes prenatal genital virilization and
    later hyperandrogenic features such as hirsutism, acne, menstrual
    irregularity, and infertility.
  cell_types:
  - preferred_term: adrenal cortical cell
    term:
      id: CL:0002097
      label: cortical cell of adrenal gland
  biological_processes:
  - preferred_term: steroid biosynthetic process
    term:
      id: GO:0006694
      label: steroid biosynthetic process
    modifier: INCREASED
  evidence:
  - reference: PMID:37176569
    reference_title: "Clinical Update on Congenital Adrenal Hyperplasia: Recommendations from a Multidisciplinary Adrenal Program."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Non-classic CAH, a milder form of CAH, is usually manifested later in life
      and is a common differential diagnosis of Polycystic Ovary Syndrome and
      should be actively evaluated during initial studies of clinical or
      biochemical hyperandrogenism.
    explanation: >-
      Supports late-presenting hyperandrogenism in nonclassic CAH and its
      clinical overlap with PCOS.
phenotypes:
- category: Endocrine
  name: Adrenal Insufficiency
  description: >-
    Cortisol deficiency is a core feature of classic CAH and can present in
    neonates or early infancy in severe forms; rare enzyme defects such as
    CYP17A1 deficiency can also produce cortisol deficiency.
  phenotype_term:
    preferred_term: Adrenal insufficiency
    term:
      id: HP:0000846
      label: Adrenal insufficiency
  subtypes:
  - Classic 21-OHD
  - Salt-Wasting 21-OHD
  - Simple-Virilizing 21-OHD
  - 17A-OHD
  evidence:
  - reference: PMID:37176569
    reference_title: "Clinical Update on Congenital Adrenal Hyperplasia: Recommendations from a Multidisciplinary Adrenal Program."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The age at diagnosis can provide some information about underlying
      mutations, with those diagnosed at birth/early infancy more likely to have
      severe enzymatic defects, which may include adrenal insufficiency, sexual
      development disorders, short stature in adulthood, hirsutism, and a higher
      risk for metabolic syndrome and infertility.
    explanation: >-
      Identifies adrenal insufficiency among severe early-diagnosed CAH
      manifestations.
  - reference: PMID:34524979
    reference_title: "The broad phenotypic spectrum of 17α-hydroxylase/17,20-lyase (CYP17A1) deficiency: a case series."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      17α-Hydroxylase/17,20-lyase deficiency (17OHD) caused by mutations in
      the CYP17A1 gene is a rare form of congenital adrenal hyperplasia
      typically characterised by cortisol deficiency, mineralocorticoid excess
      and sex steroid deficiency.
    explanation: >-
      Supports cortisol deficiency, the adrenal-insufficiency component, in
      CYP17A1-related CAH.
- category: Endocrine
  name: Salt-Wasting Electrolyte Crisis
  description: >-
    Severe mineralocorticoid deficiency can cause neonatal salt-wasting with
    hyponatremia, hyperkalemia, hypovolemia, and risk of shock.
  phenotype_term:
    preferred_term: hyponatremia
    term:
      id: HP:0002902
      label: Hyponatremia
    onset:
      onset_category: NEONATAL
  subtypes:
  - Salt-Wasting 21-OHD
  - 3B-HSD
  - Lipoid CAH
  evidence:
  - reference: PMID:37176569
    reference_title: "Clinical Update on Congenital Adrenal Hyperplasia: Recommendations from a Multidisciplinary Adrenal Program."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      CAH is characterized by the overproduction of androgen, along with
      variable degrees of cortisol and aldosterone deficiency.
    explanation: >-
      Aldosterone deficiency is the upstream hormonal defect underlying
      salt-wasting electrolyte crisis in severe CAH.
- category: Genitourinary
  name: Ambiguous Genitalia and 46,XX Virilization
  description: >-
    Prenatal androgen excess can virilize external genitalia in affected 46,XX
    infants, including clitoral hypertrophy or ambiguous genitalia.
  phenotype_term:
    preferred_term: Ambiguous genitalia
    term:
      id: HP:0000062
      label: Ambiguous genitalia
    onset:
      onset_category: CONGENITAL
  subtypes:
  - Classic 21-OHD
  - Salt-Wasting 21-OHD
  - Simple-Virilizing 21-OHD
  evidence:
  - reference: PMID:37176569
    reference_title: "Clinical Update on Congenital Adrenal Hyperplasia: Recommendations from a Multidisciplinary Adrenal Program."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The age at diagnosis can provide some information about underlying
      mutations, with those diagnosed at birth/early infancy more likely to have
      severe enzymatic defects, which may include adrenal insufficiency, sexual
      development disorders, short stature in adulthood, hirsutism, and a higher
      risk for metabolic syndrome and infertility.
    explanation: >-
      Supports early sexual-development manifestations in severe CAH.
- category: Endocrine
  name: Hirsutism
  description: >-
    Androgen excess can cause hirsutism, especially in simple-virilizing and
    nonclassic 21-hydroxylase deficiency.
  phenotype_term:
    preferred_term: Hirsutism
    term:
      id: HP:0001007
      label: Hirsutism
  subtypes:
  - Simple-Virilizing 21-OHD
  - Nonclassic 21-OHD
  evidence:
  - reference: PMID:37176569
    reference_title: "Clinical Update on Congenital Adrenal Hyperplasia: Recommendations from a Multidisciplinary Adrenal Program."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The age at diagnosis can provide some information about underlying
      mutations, with those diagnosed at birth/early infancy more likely to have
      severe enzymatic defects, which may include adrenal insufficiency, sexual
      development disorders, short stature in adulthood, hirsutism, and a higher
      risk for metabolic syndrome and infertility.
    explanation: Directly lists hirsutism among CAH manifestations.
- category: Endocrine
  name: Irregular Menstruation
  description: >-
    Hyperandrogenism in nonclassic CAH may cause menstrual irregularity and
    PCOS-like reproductive endocrine presentations.
  phenotype_term:
    preferred_term: Irregular menstruation
    term:
      id: HP:0000858
      label: Irregular menstruation
  subtypes:
  - Nonclassic 21-OHD
  evidence:
  - reference: PMID:37176569
    reference_title: "Clinical Update on Congenital Adrenal Hyperplasia: Recommendations from a Multidisciplinary Adrenal Program."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Non-classic CAH, a milder form of CAH, is usually manifested later in life
      and is a common differential diagnosis of Polycystic Ovary Syndrome and
      should be actively evaluated during initial studies of clinical or
      biochemical hyperandrogenism.
    explanation: >-
      The snippet supports PCOS-like hyperandrogenism; menstrual irregularity is
      represented as one common clinical component of that syndrome-level
      presentation.
- category: Reproductive
  name: Infertility
  description: >-
    Chronic androgen excess, adrenal rest tissue, and treatment balance can
    affect fertility in classic and nonclassic CAH.
  phenotype_term:
    preferred_term: Infertility
    term:
      id: HP:0000789
      label: Infertility
  subtypes:
  - Classic 21-OHD
  - Nonclassic 21-OHD
  evidence:
  - reference: PMID:37176569
    reference_title: "Clinical Update on Congenital Adrenal Hyperplasia: Recommendations from a Multidisciplinary Adrenal Program."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The age at diagnosis can provide some information about underlying
      mutations, with those diagnosed at birth/early infancy more likely to have
      severe enzymatic defects, which may include adrenal insufficiency, sexual
      development disorders, short stature in adulthood, hirsutism, and a higher
      risk for metabolic syndrome and infertility.
    explanation: Directly lists infertility among severe CAH risks.
- category: Cardiometabolic
  name: Hypertension
  description: >-
    Adults with classic 21-hydroxylase deficiency require surveillance for
    cardiometabolic morbidity, including hypertension; hypertension also occurs
    in mineralocorticoid-excess CAH mechanisms such as 11 beta-hydroxylase
    deficiency and 17 alpha-hydroxylase/17,20-lyase deficiency.
  phenotype_term:
    preferred_term: Hypertension
    term:
      id: HP:0000822
      label: Hypertension
  subtypes:
  - Classic 21-OHD
  - 11B-OHD
  - 17A-OHD
  evidence:
  - reference: PMID:36857009
    reference_title: "Long-term cardiometabolic morbidity in young adults with classic 21-hydroxylase deficiency congenital adrenal hyperplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Information collected included current therapy and surveillance practice
      with a particular focus on osteoporosis/osteopaenia, hyperlipidaemia, type
      2 diabetes/hyperinsulinaemia, hypertension, CV disease, obesity.
    explanation: >-
      The adult specialist-centre survey explicitly includes hypertension among
      monitored CAH comorbidity domains.
  - reference: PMID:28228528
    reference_title: "Clinical, genetic, and structural basis of congenital adrenal hyperplasia due to 11β-hydroxylase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinically, affected female newborns are profoundly virilized (Prader
      score of 4/5), and both genders display significantly advanced bone ages
      and are oftentimes hypertensive.
    explanation: >-
      Directly supports hypertension as a manifestation of CYP11B1-related
      11 beta-hydroxylase deficiency CAH.
  - reference: PMID:34524979
    reference_title: "The broad phenotypic spectrum of 17α-hydroxylase/17,20-lyase (CYP17A1) deficiency: a case series."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      17α-Hydroxylase/17,20-lyase deficiency (17OHD) caused by mutations in
      the CYP17A1 gene is a rare form of congenital adrenal hyperplasia
      typically characterised by cortisol deficiency, mineralocorticoid excess
      and sex steroid deficiency.
    explanation: >-
      Supports mineralocorticoid excess in CYP17A1-related CAH, the endocrine
      mechanism underlying hypertension in this subtype.
- category: Skeletal
  name: Osteoporosis or Osteopenia
  description: >-
    Long-term glucocorticoid exposure and disease management challenges can be
    associated with low bone density in adults with classic CAH.
  phenotype_term:
    preferred_term: Osteoporosis
    term:
      id: HP:0000939
      label: Osteoporosis
  evidence:
  - reference: PMID:36857009
    reference_title: "Long-term cardiometabolic morbidity in young adults with classic 21-hydroxylase deficiency congenital adrenal hyperplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Of 73, the patients who were treated for osteoporosis/osteopaenia,
      hyperlipidaemia, type 2 diabetes/hyperinsulinaemia, hypertension, CV
      disease, obesity were 43 (59%), 17 (23%), 16 (22%), 10 (14%), 8 (11), 3
      (4%) respectively.
    explanation: >-
      Directly reports osteoporosis/osteopaenia treatment among adults with
      classic 21-hydroxylase deficiency CAH treated for comorbidities.
- category: Growth
  name: Short Stature
  description: >-
    Severe early-diagnosed CAH can be associated with short adult stature,
    reflecting chronic androgen excess, accelerated maturation, and treatment
    balance.
  phenotype_term:
    preferred_term: Short stature
    term:
      id: HP:0004322
      label: Short stature
  subtypes:
  - Classic 21-OHD
  evidence:
  - reference: PMID:37176569
    reference_title: "Clinical Update on Congenital Adrenal Hyperplasia: Recommendations from a Multidisciplinary Adrenal Program."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The age at diagnosis can provide some information about underlying
      mutations, with those diagnosed at birth/early infancy more likely to have
      severe enzymatic defects, which may include adrenal insufficiency, sexual
      development disorders, short stature in adulthood, hirsutism, and a higher
      risk for metabolic syndrome and infertility.
    explanation: Directly identifies short stature in adulthood among severe CAH manifestations.
- category: Reproductive
  name: Testicular Adrenal Rest Tumors
  description: >-
    Testicular adrenal rest tumors are an important male reproductive
    manifestation of classic CAH and can contribute to fertility impairment;
    no specific TART HPO term was verified locally, so this phenotype is left
    unbound rather than mapped to a broad parent term.
  subtypes:
  - Classic 21-OHD
  - Salt-Wasting 21-OHD
  - Simple-Virilizing 21-OHD
  evidence:
  - reference: PMID:40921717
    reference_title: "Longitudinal Characterization and Sonographic Staging of Testicular Adrenal Rest Tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Testicular adrenal rest tumors (TART) frequently develop and are the most
      common cause of male infertility in classic congenital adrenal hyperplasia
      (CAH).
    explanation: >-
      Directly identifies TART as a frequent manifestation in classic CAH and
      links it to male infertility.
- category: Metabolic
  name: Type 2 Diabetes or Hyperinsulinemia
  description: >-
    Adults with classic 21-hydroxylase deficiency CAH require surveillance for
    abnormal glucose homeostasis, including treated type 2 diabetes or
    hyperinsulinemia.
  phenotype_term:
    preferred_term: Type II diabetes mellitus
    term:
      id: HP:0005978
      label: Type II diabetes mellitus
  evidence:
  - reference: PMID:36857009
    reference_title: "Long-term cardiometabolic morbidity in young adults with classic 21-hydroxylase deficiency congenital adrenal hyperplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Of 73, the patients who were treated for osteoporosis/osteopaenia,
      hyperlipidaemia, type 2 diabetes/hyperinsulinaemia, hypertension, CV
      disease, obesity were 43 (59%), 17 (23%), 16 (22%), 10 (14%), 8 (11), 3
      (4%) respectively.
    explanation: >-
      Directly reports treated type 2 diabetes/hyperinsulinemia among adult CAH
      comorbidity cases.
biochemical:
- name: Elevated 17-hydroxyprogesterone
  notes: >-
    21-hydroxylase deficiency causes accumulation of steroid precursors before
    the enzymatic block, including 17-hydroxyprogesterone.
  evidence:
  - reference: PMID:28938470
    reference_title: "Genetic Disruption of 21-Hydroxylase in Zebrafish Causes Interrenal Hyperplasia."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Furthermore, Cyp21a2-deficient larvae had a typical steroid profile, with
      reduced concentrations of cortisol and increased concentrations of
      17-hydroxyprogesterone and 21-deoxycortisol.
    explanation: >-
      The zebrafish 21OHD model recapitulates the expected steroid precursor
      accumulation pattern.
- name: Reduced Cortisol
  notes: >-
    Reduced cortisol synthesis is the core biochemical abnormality linking CAH
    enzyme deficiency to adrenal insufficiency and ACTH-driven adrenal
    stimulation.
  evidence:
  - reference: PMID:38791102
    reference_title: "A Humanized and Viable Animal Model for Congenital Adrenal Hyperplasia-CYP21A2-R484Q Mutant Mouse."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Mutant mice showed hyperplastic adrenals and exhibited reduced levels of
      corticosterone and 11-deoxycorticosterone and an increase in progesterone.
    explanation: >-
      In the humanized mouse model, reduced glucocorticoid-pathway products and
      increased precursors support the blocked steroidogenesis model.
diagnosis:
- name: 17-hydroxyprogesterone biochemical testing
  description: >-
    Biochemical screening and confirmatory testing for 21-hydroxylase
    deficiency centers on 17-hydroxyprogesterone measurement, including newborn
    dried-blood-spot screening in many programs.
  evidence:
  - reference: PMID:31984156
    reference_title: "Newborn Screening for Congenital Hypothyroidism, Congenital Adrenal Hyperplasia, and Glucose-6-Phosphate Dehydrogenase Deficiency for Improving Health Care in India."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      From January 2008 through December 2017, 13,376 newborns were screened for
      congenital hypothyroidism (CH), congenital adrenal hyperplasia (CAH), and
      glucose-6-phosphate dehydrogenase (G6PD) deficiency at Sir Ganga Ram
      Hospital, India, by measuring G6PD activity, thyroid-stimulating hormone,
      and 17-hydroxyprogesterone on dried blood specimens.
    explanation: >-
      Demonstrates population newborn screening for CAH using dried-blood-spot
      17-hydroxyprogesterone.
- name: CYP21A2 genetic testing
  description: >-
    Molecular testing for CYP21A2 supports diagnosis, genotype-phenotype
    interpretation, family counseling, and recurrence-risk assessment.
  diagnosis_term:
    preferred_term: genetic testing
    term:
      id: MAXO:0000127
      label: genetic testing
  evidence:
  - reference: PMID:39911519
    reference_title: "Genetics in Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency and Clinical Implications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      21OHD represents one of the most complex and at the same time intriguing
      topics in human genetics and its molecular diagnosis involves ongoing
      challenges.
    explanation: >-
      Supports the role and complexity of molecular diagnosis for CYP21A2-related
      21-hydroxylase deficiency.
treatments:
- name: Glucocorticoid replacement
  description: >-
    Glucocorticoid therapy replaces deficient cortisol and suppresses excess
    ACTH-driven adrenal androgen production; treatment must balance androgen
    control against glucocorticoid-related complications.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: therapeutic hydrocortisone
      term:
        id: NCIT:C555
        label: Therapeutic Hydrocortisone
  target_mechanisms:
  - target: Cortisol and Aldosterone Deficiency
    treatment_effect: RESTORES
    description: Glucocorticoid replacement restores deficient cortisol action.
  - target: ACTH-Driven Adrenal Hyperplasia and Androgen Excess
    treatment_effect: INHIBITS
    description: >-
      Adequate glucocorticoid replacement suppresses ACTH-driven adrenal
      androgen overproduction.
  evidence:
  - reference: PMID:38828955
    reference_title: "Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Adrenal insufficiency in patients with classic 21-hydroxylase deficiency
      congenital adrenal hyperplasia (CAH) is treated with glucocorticoid
      replacement therapy.
    explanation: Directly supports glucocorticoid replacement as standard CAH therapy.
- name: Mineralocorticoid replacement
  description: >-
    Fludrocortisone replaces mineralocorticoid activity in salt-wasting CAH and
    is used with glucocorticoids in many adults with classic disease.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: fludrocortisone
      term:
        id: NCIT:C71629
        label: Fludrocortisone
  target_mechanisms:
  - target: Cortisol and Aldosterone Deficiency
    treatment_effect: RESTORES
    description: Fludrocortisone replaces deficient mineralocorticoid action.
  target_phenotypes:
  - preferred_term: hyponatremia
    term:
      id: HP:0002902
      label: Hyponatremia
  evidence:
  - reference: PMID:36857009
    reference_title: "Long-term cardiometabolic morbidity in young adults with classic 21-hydroxylase deficiency congenital adrenal hyperplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Of these, 126 (52%) were females and 174 (71%) received fludrocortisone in
      addition to glucocorticoids.
    explanation: >-
      Documents frequent combined fludrocortisone and glucocorticoid treatment
      in adults with classic 21-hydroxylase deficiency CAH.
- name: Crinecerfont adjunct therapy
  description: >-
    Crinecerfont is an oral corticotropin-releasing factor type 1 receptor
    antagonist that reduces ACTH-driven androgen excess and enables lower
    glucocorticoid doses in classic CAH.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: crinecerfont
      term:
        id: NCIT:C174708
        label: Crinecerfont
  target_mechanisms:
  - target: ACTH-Driven Adrenal Hyperplasia and Androgen Excess
    treatment_effect: INHIBITS
    description: >-
      CRF1 receptor antagonism lowers ACTH drive and helps reduce adrenal
      androgen excess.
  evidence:
  - reference: PMID:38828955
    reference_title: "Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Crinecerfont, an oral corticotropin-releasing factor type 1 receptor
      antagonist, lowered androstenedione levels in phase 2 trials involving
      patients with CAH.
    explanation: >-
      Identifies the mechanism and prior androgen-lowering evidence for
      crinecerfont in CAH.
  - reference: PMID:38828955
    reference_title: "Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Among patients with CAH, the use of crinecerfont resulted in a greater
      decrease from baseline in the mean daily glucocorticoid dose, including a
      reduction to the physiologic range, than placebo following evaluation of
      adrenal androgen levels.
    explanation: >-
      Phase 3 evidence supports a glucocorticoid-sparing benefit while monitoring
      adrenal androgen control.
- name: CYP21A2 gene therapy
  description: >-
    AAV-mediated CYP21A2 gene therapy is investigational and is designed to
    restore adrenal steroidogenesis upstream of hormone deficiency and androgen
    shunting.
  treatment_term:
    preferred_term: gene therapy
    term:
      id: MAXO:0001001
      label: gene therapy
  target_mechanisms:
  - target: CYP21A2 21-Hydroxylase Deficiency
    treatment_effect: RESTORES
    description: >-
      CYP21A2 delivery aims to restore the deficient steroidogenic enzyme step.
  evidence:
  - reference: PMID:36982440
    reference_title: "Models of Congenital Adrenal Hyperplasia for Gene Therapies Testing."
    supports: PARTIAL
    evidence_source: OTHER
    snippet: >-
      Congenital adrenal hyperplasia (CAH) is an example of such a potentially
      treatable monogenic disease.
    explanation: >-
      Supports gene therapy as a plausible investigational strategy while not
      establishing clinical efficacy.
clinical_trials:
- name: NCT04490915
  phase: PHASE_III
  status: ACTIVE_NOT_RECRUITING
  description: >-
    Phase 3 trial of crinecerfont versus placebo in adults with classic CAH due
    to 21-hydroxylase deficiency, followed by open-label treatment.
  evidence:
  - reference: clinicaltrials:NCT04490915
    reference_title: "A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Adult Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This is a Phase 3 study to evaluate the efficacy, safety, and tolerability
      of crinecerfont versus placebo administered for 24 weeks in approximately
      165 adult participants with classic CAH due to 21-hydroxylase deficiency.
    explanation: >-
      The trial record directly describes the crinecerfont CAH phase 3 study.
- name: NCT04783181
  phase: PHASE_I
  status: ACTIVE_NOT_RECRUITING
  description: >-
    Phase 1/2 first-in-human AAV5-based BBP-631 CYP21A2 gene therapy study for
    adults with classic CAH.
  evidence:
  - reference: clinicaltrials:NCT04783181
    reference_title: "A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of the Safety and Efficacy of Gene Therapy for Congenital Adrenal Hyperplasia Through Administration of an Adeno-Associated Virus (AAV) Serotype 5-Based Recombinant Vector Encoding the Human CYP21A2 Gene"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This study is designed to evaluate the safety, tolerability, and efficacy
      of AAV5 based BBP-631 in adult participants diagnosed with classic
      congenital adrenal hyperplasia.
    explanation: >-
      The trial record directly describes an AAV5 BBP-631 gene therapy study in
      classic CAH.
references:
- reference: DOI:10.3390/jcm12093128
  title: "Clinical Update on Congenital Adrenal Hyperplasia: Recommendations from a Multidisciplinary Adrenal Program."
  found_in:
  - Congenital_Adrenal_Hyperplasia-deep-research-falcon.md
  findings: []
- reference: DOI:10.1210/jendso/bvaf018
  title: Genetics in Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency and Clinical Implications.
  found_in:
  - Congenital_Adrenal_Hyperplasia-deep-research-falcon.md
  findings: []
- reference: DOI:10.4274/jcrpe.galenos.2024.2024-6-6-s
  title: Clinical, biochemical and molecular characteristics of congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
  found_in:
  - Congenital_Adrenal_Hyperplasia-deep-research-falcon.md
  findings: []
- reference: DOI:10.1210/jendso/bvaa152
  title: Attention-deficit/hyperactivity disorder among US children and adolescents with congenital adrenal hyperplasia.
  found_in:
  - Congenital_Adrenal_Hyperplasia-deep-research-falcon.md
  findings: []
- reference: DOI:10.1210/js.2019-00122
  title: "Increased Risk of Autoimmune Disorders in 21-Hydroxylase Deficiency: A Swedish Population-Based National Cohort Study."
  found_in:
  - Congenital_Adrenal_Hyperplasia-deep-research-falcon.md
  findings: []
- reference: DOI:10.1056/nejmoa2404656
  title: Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia.
  found_in:
  - Congenital_Adrenal_Hyperplasia-deep-research-falcon.md
  findings: []
- reference: DOI:10.1007/s12020-023-03330-w
  title: Long-term cardiometabolic morbidity in young adults with classic 21-hydroxylase deficiency congenital adrenal hyperplasia.
  found_in:
  - Congenital_Adrenal_Hyperplasia-deep-research-falcon.md
  findings: []
- reference: DOI:10.1055/s-0039-1698424
  title: Newborn Screening for Congenital Hypothyroidism, Congenital Adrenal Hyperplasia, and Glucose-6-Phosphate Dehydrogenase Deficiency for Improving Health Care in India.
  found_in:
  - Congenital_Adrenal_Hyperplasia-deep-research-falcon.md
  findings: []
- reference: DOI:10.1210/en.2017-00549
  title: Genetic Disruption of 21-Hydroxylase in Zebrafish Causes Interrenal Hyperplasia.
  found_in:
  - Congenital_Adrenal_Hyperplasia-deep-research-falcon.md
  findings: []
- reference: DOI:10.3390/ijms25105062
  title: A Humanized and Viable Animal Model for Congenital Adrenal Hyperplasia-CYP21A2-R484Q Mutant Mouse.
  found_in:
  - Congenital_Adrenal_Hyperplasia-deep-research-falcon.md
  findings: []
- reference: DOI:10.3390/ijms24065365
  title: Models of Congenital Adrenal Hyperplasia for Gene Therapies Testing.
  found_in:
  - Congenital_Adrenal_Hyperplasia-deep-research-falcon.md
  findings: []
- reference: DOI:10.1210/jendso/bvac062
  title: CYP21A2 Gene Expression in a Humanized 21-Hydroxylase Mouse Model Does Not Affect Adrenocortical Morphology and Function.
  found_in:
  - Congenital_Adrenal_Hyperplasia-deep-research-falcon.md
  findings: []
- reference: DOI:10.3390/metabo15020089
  title: "Metabolic syndrome spectrum in children with classic congenital adrenal hyperplasia: a comprehensive review."
  found_in:
  - Congenital_Adrenal_Hyperplasia-deep-research-falcon.md
  findings: []
- reference: DOI:10.70315/uloap.ulcnu.2025.0201002
  title: "Congenital adrenal hyperplasia: a clinical review."
  found_in:
  - Congenital_Adrenal_Hyperplasia-deep-research-falcon.md
  findings: []
- reference: DOI:10.4274/jcrpe.galenos.2024.2024-6-10-s
  title: Antenatal diagnosis and treatment in congenital adrenal hyperplasia due to 21-hydroxylase deficiency and congenital adrenal hyperplasia screening in newborns.
  found_in:
  - Congenital_Adrenal_Hyperplasia-deep-research-falcon.md
  findings: []
- reference: DOI:10.1186/s42826-024-00212-8
  title: "Non-classical animal models for studying adrenal diseases: advantages, limitations, and implications for research."
  found_in:
  - Congenital_Adrenal_Hyperplasia-deep-research-falcon.md
  findings: []
- reference: DOI:10.4274/jcrpe.galenos.2024.2024-6-21-s
  title: Congenital adrenal hyperplasia due to rare enzyme deficiencies.
  found_in:
  - Congenital_Adrenal_Hyperplasia-deep-research-falcon.md
  findings: []
- reference: DOI:10.1016/b978-0-12-416006-4.00026-0
  title: Animal models of adrenal genetic disorders.
  found_in:
  - Congenital_Adrenal_Hyperplasia-deep-research-falcon.md
  findings: []
datasets:
📚

References & Deep Research

References

18
DOI:10.3390/jcm12093128
Clinical Update on Congenital Adrenal Hyperplasia: Recommendations from a Multidisciplinary Adrenal Program.
No top-level findings curated for this source.
DOI:10.1210/jendso/bvaf018
Genetics in Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency and Clinical Implications.
No top-level findings curated for this source.
DOI:10.4274/jcrpe.galenos.2024.2024-6-6-s
Clinical, biochemical and molecular characteristics of congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
No top-level findings curated for this source.
DOI:10.1210/jendso/bvaa152
Attention-deficit/hyperactivity disorder among US children and adolescents with congenital adrenal hyperplasia.
No top-level findings curated for this source.
DOI:10.1210/js.2019-00122
Increased Risk of Autoimmune Disorders in 21-Hydroxylase Deficiency: A Swedish Population-Based National Cohort Study.
No top-level findings curated for this source.
DOI:10.1056/nejmoa2404656
Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia.
No top-level findings curated for this source.
DOI:10.1007/s12020-023-03330-w
Long-term cardiometabolic morbidity in young adults with classic 21-hydroxylase deficiency congenital adrenal hyperplasia.
No top-level findings curated for this source.
DOI:10.1055/s-0039-1698424
Newborn Screening for Congenital Hypothyroidism, Congenital Adrenal Hyperplasia, and Glucose-6-Phosphate Dehydrogenase Deficiency for Improving Health Care in India.
No top-level findings curated for this source.
DOI:10.1210/en.2017-00549
Genetic Disruption of 21-Hydroxylase in Zebrafish Causes Interrenal Hyperplasia.
No top-level findings curated for this source.
DOI:10.3390/ijms25105062
A Humanized and Viable Animal Model for Congenital Adrenal Hyperplasia-CYP21A2-R484Q Mutant Mouse.
No top-level findings curated for this source.
DOI:10.3390/ijms24065365
Models of Congenital Adrenal Hyperplasia for Gene Therapies Testing.
No top-level findings curated for this source.
DOI:10.1210/jendso/bvac062
CYP21A2 Gene Expression in a Humanized 21-Hydroxylase Mouse Model Does Not Affect Adrenocortical Morphology and Function.
No top-level findings curated for this source.
DOI:10.3390/metabo15020089
Metabolic syndrome spectrum in children with classic congenital adrenal hyperplasia: a comprehensive review.
No top-level findings curated for this source.
DOI:10.70315/uloap.ulcnu.2025.0201002
Congenital adrenal hyperplasia: a clinical review.
No top-level findings curated for this source.
DOI:10.4274/jcrpe.galenos.2024.2024-6-10-s
Antenatal diagnosis and treatment in congenital adrenal hyperplasia due to 21-hydroxylase deficiency and congenital adrenal hyperplasia screening in newborns.
No top-level findings curated for this source.
DOI:10.1186/s42826-024-00212-8
Non-classical animal models for studying adrenal diseases: advantages, limitations, and implications for research.
No top-level findings curated for this source.
DOI:10.4274/jcrpe.galenos.2024.2024-6-21-s
Congenital adrenal hyperplasia due to rare enzyme deficiencies.
No top-level findings curated for this source.
DOI:10.1016/b978-0-12-416006-4.00026-0
Animal models of adrenal genetic disorders.
No top-level findings curated for this source.

Deep Research

1
Falcon ▸
Disease Characteristics Research Template
Edison Scientific Literature 51 citations 2026-05-07T09:20:03.345763

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

  • Disease Name: Congenital Adrenal Hyperplasia
  • MONDO ID: (if available)
  • Category: Mendelian

Research Objectives

Please provide a comprehensive research report on Congenital Adrenal Hyperplasia covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

  • What is the disease? Provide a concise overview.
  • What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
  • What are the common synonyms and alternative names?
  • Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

  • Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
  • Risk Factors:

    Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

  • Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  • Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
  • Protective Factors:

    Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

  • Genetic protective factors (protective variants, modifier alleles)
  • Environmental protective factors (diet, lifestyle, exposures that reduce risk)
  • Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

    Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

  • Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

    Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

  • Pathogenic Variants:
  • Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  • Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  • Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  • Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  • Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
  • Functional consequences (loss of function, gain of function, dominant negative)
  • Modifier Genes: Genes that modify disease severity or expression
  • Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

    Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

  • Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

    Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

  • Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

    Search first: CDC databases, WHO, PubMed, NHANES

  • Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

    Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

  • Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

    Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

  • Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

    Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

  • Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

    Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

  • Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

    Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

  • Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

    Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

  • Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

    Search first: PubMed, Gene Ontology, Reactome

  • Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

    Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

  • Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Molecular Profiling (if available):
  • Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  • Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  • Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
  • Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  • Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
  • Advanced Technologies (if applicable):
  • Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  • Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
  • Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  • Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

  • Organ Level:
  • Primary organs directly affected
  • Secondary organ involvement (complications, secondary effects)
  • Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

    Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

  • Tissue and Cell Level:
  • Specific tissue types affected (epithelial, connective, muscle, nervous)
  • Specific cell populations targeted (with Cell Ontology terms)

    Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

  • Subcellular Level:
  • Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

    Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

  • Localization:
  • Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
  • Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

  • Onset:
  • Typical age of onset (congenital, pediatric, adult, geriatric)
  • Onset pattern (acute, subacute, chronic, insidious)

    Search first: OMIM, Orphanet, HPO, PubMed

  • Progression:
  • Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
  • Progression rate (rapid, slow, variable)
  • Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  • Disease duration (self-limited, chronic lifelong)

    Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

  • Patterns:
  • Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
  • Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

  • Epidemiology:
  • Prevalence (cases per 100,000 at given time)
  • Incidence (new cases per 100,000 per year)

    Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

  • For Genetic Etiology:
  • Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  • Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
  • Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
  • Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
  • Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
  • Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
  • Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
  • Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
  • Population Demographics:
  • Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  • Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  • Geographic distribution of specific variants
  • Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
  • Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

  • Clinical Tests:
  • Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
  • Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  • Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
  • Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
  • Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
  • Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
  • Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
  • Genetic Testing:

    Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

  • Overview of recommended genetic testing approach
  • Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
  • Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
  • Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
  • Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
  • Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
  • Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
  • FISH > Search first: ClinVar, cytogenetics databases, PubMed
  • Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
  • Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
  • Omics-Based Diagnostics (if applicable):
  • RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
  • Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
  • Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
  • Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
  • Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
  • Clinical Criteria:
  • Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
  • Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
  • Screening:
  • Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

  • Survival and Mortality:
  • Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
  • Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
  • Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
  • Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
  • Morbidity and Function:
  • Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
  • Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
  • Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
  • Disease Course:
  • Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
  • Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
  • Prediction:
  • Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
  • Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

  • Pharmacotherapy:
  • Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  • Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
  • Advanced Therapeutics:
  • Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  • Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
  • RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
  • Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  • Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
  • Surgical and Interventional:
  • Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
  • Supportive and Rehabilitative:
  • Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
  • Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
  • Experimental:
  • Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
  • Treatment Outcomes:
  • Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
  • Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
  • Treatment Strategy:
  • Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
  • Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
  • Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

  • Prevention Levels:
  • Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
  • Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
  • Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
  • Immunization: Vaccine strategies (if applicable)

    Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

  • Screening and Early Detection:
  • Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
  • Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
  • Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
  • Behavioral Interventions: Lifestyle modifications to reduce risk

    Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

  • Counseling: Genetic counseling (risk assessment, family planning guidance)

    Search first: NSGC resources, ACMG guidelines, GeneReviews

  • Public Health:
  • Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
  • Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
  • Prophylaxis: Preventive medications or procedures

    Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

  • Taxonomy: Species affected (with NCBI Taxon identifiers)

    Search first: NCBI Taxonomy

  • Breed: Specific breeds affected (with VBO identifiers if applicable)

    Search first: VBO (Vertebrate Breed Ontology)

  • Gene: Orthologous genes in other species (with NCBI Gene IDs)

    Search first: NCBI Gene

  • Natural Disease:
  • Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  • Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
  • Comparative Biology:
  • Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
  • Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
  • Transmission (if applicable):
  • Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
  • Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

  • Model Types:
  • Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
  • Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  • Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
  • Genetic Models:
  • Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
  • Model Characteristics:
  • Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
  • Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
  • Applications:
  • Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
  • Resources:
  • Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic and clinical claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes from abstracts where possible to support key statements
  • Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Congenital Adrenal Hyperplasia (CAH) — Disease Characteristics Research Report (Mendelian)

Target disease and scope

Congenital adrenal hyperplasia (CAH) is a group of inherited disorders of adrenal steroidogenesis; ~95–99% of CAH is due to 21-hydroxylase deficiency (21-OHD) caused by pathogenic variants in CYP21A2, leading to cortisol deficiency with variable aldosterone deficiency and androgen excess. (concolino2025geneticsincongenital pages 1-2, gunes2025clinicalbiochemicaland pages 1-2, uslar2023clinicalupdateon pages 3-6)

This report emphasizes 21-OHD CAH (classic salt-wasting/simple virilizing and nonclassic) while also summarizing rarer enzymatic etiologies.

1. Disease information

1.1 Concise overview

CAH (21-OHD) results from reduced 21-hydroxylase activity in the adrenal cortex. The defect decreases cortisol synthesis; reduced cortisol negative feedback increases ACTH drive, promoting adrenal hyperplasia and shunting steroid precursors into androgen pathways, causing prenatal virilization in some 46,XX fetuses and postnatal hyperandrogenism in both sexes. (concolino2025geneticsincongenital pages 1-2, uslar2023clinicalupdateon pages 3-6)

1.2 Key identifiers (available in retrieved evidence)

  • MONDO: MONDO_0018479 (“congenital adrenal hyperplasia”) via Open Targets disease record. (OpenTargets Search: Congenital adrenal hyperplasia)
  • ICD-10-CM: E25.0 used for administrative/claims identification of CAH in US datasets and Swedish national registers. (harasymiw2020attentiondeficithyperactivitydisorderamong pages 3-3, falhammar2019increasedriskof pages 2-3)

Not found in retrieved full texts for this run (thus not evidence-backed here): OMIM disease entry numbers, Orphanet ORPHA codes, MeSH headings, ICD-11 codes.

1.3 Common synonyms / alternative names

  • “Adrenogenital syndrome” appears as a closely related disease term in Open Targets and in ICD coding contexts. (OpenTargets Search: Congenital adrenal hyperplasia, harasymiw2020attentiondeficithyperactivitydisorderamong pages 3-3)

1.4 Evidence provenance type

This report integrates: - Aggregated disease-level resources (Open Targets MONDO mapping; reviews). (OpenTargets Search: Congenital adrenal hyperplasia, uslar2023clinicalupdateon pages 3-6, concolino2025geneticsincongenital pages 1-2) - Human clinical studies/registries/claims (NEJM phase 3 trial; national cohort; multicenter surveys; newborn screening cohort). (auchus2024phase3trial pages 1-3, falhammar2019increasedriskof pages 1-2, righi2023longtermcardiometabolicmorbidity pages 1-2, verma2020newbornscreeningfor pages 1-2) - Model organism studies/reviews (zebrafish, mouse; gene-therapy model reviews). (eachus2017geneticdisruptionof pages 1-2, thirumalasetty2024ahumanizedand pages 1-2, glazova2023modelsofcongenital pages 2-4)

2. Etiology

2.1 Disease causal factors

Primary cause (genetic): autosomal recessive pathogenic variation in steroidogenic enzymes, most commonly CYP21A2 (21-hydroxylase). (concolino2025geneticsincongenital pages 1-2, gunes2025clinicalbiochemicaland pages 1-2)

Genetic architecture of CYP21A2 locus: The 2023 multidisciplinary review summarizes that CYP21A2 sits in the HLA region and that pathogenic variants frequently arise from recombination with the pseudogene (microconversions ~75%, unequal crossing-over 20–25%, de novo 1–2%), with >200 known variants but ~10 accounting for ~90% of cases. (uslar2023clinicalupdateon pages 6-7)

Rare CAH etiologies: include 11β-hydroxylase deficiency (CYP11B1), 3β-HSD deficiency (HSD3B2), 17-hydroxylase deficiency (CYP17A1), and lipoid CAH (STAR). (OpenTargets Search: Congenital adrenal hyperplasia)

2.2 Risk factors

  • Inheritance pattern: CAH due to 21-OHD is autosomal recessive. (concolino2025geneticsincongenital pages 1-2, gunes2025clinicalbiochemicaland pages 1-2)
  • Carrier frequency (severe alleles): one multidisciplinary program review reports ~1 in 60 (2%) prevalence of severe allelic variants in the population. (uslar2023clinicalupdateon pages 9-10)

2.3 Protective factors

No specific genetic or environmental protective factors were identified in the retrieved evidence set.

2.4 Gene–environment interactions

The retrieved evidence emphasizes genetic causation and treatment-related complications rather than clear gene–environment interaction effects.

3. Phenotypes (clinical spectrum)

3.1 Current clinical classification

A widely used clinical framework divides 21-OHD into: - Classic salt-wasting (SW): typically 65–75% of classic cases, residual activity <1%, neonatal adrenal insufficiency/salt-wasting crisis and 46,XX virilization. (uslar2023clinicalupdateon pages 3-6) - Classic simple virilizing (SV): 25–35% of classic, residual activity ~1–2%, hyperandrogenism with less/minimal mineralocorticoid deficiency. (uslar2023clinicalupdateon pages 3-6) - Nonclassic (NCCAH): residual activity ~20–50%, later-onset hyperandrogenism (acne, hirsutism, oligomenorrhea/infertility), commonly considered in PCOS differential diagnosis. (uslar2023clinicalupdateon pages 3-6)

A 2025 pediatric endocrine review also emphasizes that phenotype likely represents a continuum rather than discrete bins. (gunes2025clinicalbiochemicaland pages 1-2)

3.2 Phenotype list with ontology suggestions

Key phenotype annotations (including quantitative frequencies where available) are summarized in the table artifact below.

Phenotype (plain) Phenotype type Typical onset Frequency / notes Suggested HPO term(s) Supporting citations
Salt-wasting crisis with hyponatremia, hyperkalemia, hypovolemia/shock Symptom/sign/laboratory abnormality Neonatal / early infancy Classic salt-wasting CAH accounts for 65–75% of classic cases; residual 21-hydroxylase activity typically <1%; neonatal crises may be life-threatening if unrecognized Salt-wasting HP:0002013; Hyponatremia HP:0002902; Hyperkalemia HP:0002153; Shock HP:0001278 (uslar2023clinicalupdateon pages 3-6, gunes2025clinicalbiochemicaland pages 1-2, concolino2025geneticsincongenital pages 1-2)
Virilized / ambiguous external genitalia in 46,XX infants Physical manifestation / sign Prenatal, recognized at birth Typical of classic CAH; females may show varying degrees of virilization (Prader 1–5) from fetal androgen excess Ambiguous genitalia HP:0000062; Clitoromegaly HP:0000058; Abnormality of the labia HP:0000060 (uslar2023clinicalupdateon pages 3-6, abalı2025antenataldiagnosisand pages 1-2, concolino2025geneticsincongenital pages 1-2)
Precocious pubarche / premature pubic hair Sign Early childhood Characteristic of simple virilizing classic CAH and can occur in NCCAH due to androgen excess Precocious pubarche HP:0000878 (gunes2025clinicalbiochemicaland pages 1-2, uslar2023clinicalupdateon pages 3-6)
Accelerated linear growth Sign Childhood Seen in classic CAH, especially simple virilizing disease; reflects chronic androgen excess Accelerated growth HP:0001510 (gunes2025clinicalbiochemicaland pages 1-2)
Advanced bone age Laboratory / imaging-associated abnormality Childhood Common in simple virilizing CAH and progressive androgen excess states Advanced skeletal maturation HP:0002750 (gunes2025clinicalbiochemicaland pages 1-2)
Acne Symptom / sign Adolescence to adulthood; can occur earlier in NCCAH Common hyperandrogenic presentation in nonclassic CAH Acne HP:0001074 (gunes2025clinicalbiochemicaland pages 1-2, uslar2023clinicalupdateon pages 3-6)
Hirsutism Sign Adolescence to adulthood Common in nonclassic CAH; part of late-onset hyperandrogenism spectrum Hirsutism HP:0001007 (gunes2025clinicalbiochemicaland pages 1-2, uslar2023clinicalupdateon pages 3-6, uslar2023clinicalupdateon pages 9-10)
Menstrual irregularity / oligomenorrhea / amenorrhea Symptom / sign Adolescence to adulthood Common in nonclassic CAH women; important differential with PCOS Irregular menstruation HP:0000858; Oligomenorrhea HP:0000879; Amenorrhea HP:0000141 (gunes2025clinicalbiochemicaland pages 1-2, uslar2023clinicalupdateon pages 3-6)
Infertility / reduced fertility Clinical outcome / symptom Adolescence to adulthood In untreated classic CAH, up to 90% of women may experience infertility; NCCAH infertility and miscarriage risk can improve with hydrocortisone, with conception rates reported close to 90% under treatment in cited review Infertility HP:0000789; Female infertility HP:0008209 (uslar2023clinicalupdateon pages 9-10)
Testicular adrenal rest tumors (TARTs) Physical manifestation / imaging finding Childhood through adulthood Prevalence reported as ~20% in children and 50–80% in adults; surveillance with testicular ultrasound from age 8 years every 2 years was recommended in one review Testicular adrenal rest tumor HP:0034827; Abnormal testicular morphology HP:0000119 (uslar2023clinicalupdateon pages 9-10)
Obesity / increased adiposity Comorbidity / sign Childhood through adulthood Common long-term comorbidity; in one adult cohort obesity screening occurred in 97% of centers; prevalence varied by country, e.g. 41% in UK cohort, and all obese patients in one surveyed cohort had salt-wasting CAH Obesity HP:0001513; Increased body mass index HP:0001956 (righi2023longtermcardiometabolicmorbidity pages 4-5, righi2023longtermcardiometabolicmorbidity pages 2-3, righi2023longtermcardiometabolicmorbidity pages 1-2, zaric2025metabolicsyndromespectrum pages 1-2)
Hypertension / elevated systolic blood pressure Comorbidity / sign Childhood through adulthood In adult cohort, 10/244 were treated for hypertension; pediatric review reported 58% systolic hypertension and 24% diastolic hypertension in one CCAH study, with loss of nocturnal dipping particularly in salt-wasting patients Hypertension HP:0000822 (righi2023longtermcardiometabolicmorbidity pages 1-2, zaric2025metabolicsyndromespectrum pages 12-14)
Osteoporosis / osteopenia Comorbidity / sign Adulthood (can emerge earlier with chronic treatment exposure) Most common treated comorbidity in one adult survey: 43/73 (59%) of treated comorbidity cases received therapy for osteoporosis/osteopenia; bone screening performed by 81% of centers, mainly DXA Osteoporosis HP:0000939; Osteopenia HP:0000938 (righi2023longtermcardiometabolicmorbidity pages 4-5, righi2023longtermcardiometabolicmorbidity pages 2-3, righi2023longtermcardiometabolicmorbidity pages 1-2)
Type 2 diabetes / insulin resistance / abnormal glucose homeostasis Comorbidity / laboratory abnormality Childhood to adulthood Adult cohort: 16/73 (22%) of treated comorbidity cases had type 2 diabetes/hyperinsulinaemia; pediatric review found insulin resistance frequently increased in classic CAH Insulin resistance HP:0000855; Hyperinsulinemia HP:0003074; Type II diabetes mellitus HP:0005978 (righi2023longtermcardiometabolicmorbidity pages 1-2, zaric2025metabolicsyndromespectrum pages 1-2, zaric2025metabolicsyndromespectrum pages 12-14)
Autoimmune disorders increased risk Comorbidity Usually later childhood to adulthood Swedish national cohort: autoimmune disorders in 7.4% of 21OHD patients vs 5.1% of controls; RR 1.47 (95% CI 1.13–1.91), with increased autoimmune endocrine and thyroid disease Autoimmunity HP:0002960; Autoimmune thyroiditis HP:0002726 (falhammar2019increasedriskof pages 1-2)

Table: This table summarizes major clinical phenotypes and comorbidities across classic salt-wasting, simple virilizing, and nonclassic 21-hydroxylase deficiency CAH. It includes suggested HPO mappings and recent quantitative frequencies where available to support knowledge-base phenotype annotation.

Quality-of-life burdens are repeatedly linked to chronic androgen excess, adrenal crises, growth concerns, reproductive challenges, and long-term metabolic/bone outcomes, with the management goal framed as optimizing long-term health and daily functioning while avoiding glucocorticoid overtreatment. (uslar2023clinicalupdateon pages 3-6, harris2025congenitaladrenalhyperplasia pages 7-9)

4. Genetic / molecular information

4.1 Causal genes (human)

Primary genes supported in this evidence set: - CYP21A2 (21-hydroxylase deficiency; majority of CAH). (concolino2025geneticsincongenital pages 1-2, gunes2025clinicalbiochemicaland pages 1-2) - Additional CAH-related steroidogenesis genes emphasized for rarer CAH forms include CYP11B1, HSD3B2, CYP17A1, STAR. (OpenTargets Search: Congenital adrenal hyperplasia)

Open Targets also associates CAH with these genes and additional steroidogenic components (e.g., CYP11A1, POR), reflecting broader steroidogenesis biology and variant databases. (OpenTargets Search: Congenital adrenal hyperplasia)

4.2 Pathogenic variants and functional consequence

  • For 21-OHD, loss of 21-hydroxylase reduces conversion of 17-hydroxyprogesterone to 11-deoxycortisol, producing precursor accumulation and downstream androgen excess, and increased ACTH drive. (concolino2025geneticsincongenital pages 1-2)
  • A practical genotype grouping used clinically links residual activity to phenotype: Group A (no activity → SW), Group B (1–10% → SV), Group C (20–60% → NCCAH). (uslar2023clinicalupdateon pages 6-7)

4.3 Modifier genes / contiguous gene syndromes

The retrieved evidence set does not include direct primary-data details on modifier genes, but highlights that complex HLA-locus recombination events contribute to genotypes and diagnostic complexity. (uslar2023clinicalupdateon pages 6-7)

4.4 Epigenetics and chromosomal abnormalities

No CAH-specific epigenetic signatures or recurrent chromosomal abnormalities were identified in the retrieved evidence set.

5. Environmental information

CAH is principally monogenic. Environmental exposures are not described as causal in the retrieved sources; most “environmental” relevance is via stressors triggering adrenal crisis in cortisol-deficient individuals and via treatment-related adverse effects (chronic supraphysiologic glucocorticoid exposure). (harris2025congenitaladrenalhyperplasia pages 7-9, righi2023longtermcardiometabolicmorbidity pages 1-2)

6. Mechanism / pathophysiology

6.1 Causal chain (21-OHD)

  1. CYP21A2 deficiency → impaired 21-hydroxylation of progesterone/17-hydroxyprogesterone. (concolino2025geneticsincongenital pages 1-2)
  2. Reduced cortisol ± aldosterone production → loss of negative feedback on hypothalamic–pituitary axis. (concolino2025geneticsincongenital pages 1-2)
  3. ACTH elevation → adrenal cortical hyperplasia and increased flux through androgen synthesis pathways. (concolino2025geneticsincongenital pages 1-2, uslar2023clinicalupdateon pages 3-6)
  4. Clinical manifestations: adrenal insufficiency (including neonatal salt-wasting crisis in SW), prenatal virilization in some 46,XX fetuses, postnatal hyperandrogenism (precocious pubarche, acne, hirsutism, menstrual irregularity, fertility issues), and long-term metabolic/bone comorbidity partly mediated by both disease and treatment exposure. (uslar2023clinicalupdateon pages 3-6, gunes2025clinicalbiochemicaland pages 1-2, righi2023longtermcardiometabolicmorbidity pages 1-2)

6.2 Pathway visualization evidence

The steroidogenesis pathway and the CYP21A2 step are shown in a recent genetics review figure (including 17-hydroxyprogesterone and the 21-hydroxylase-catalyzed conversion). (concolino2025geneticsincongenital media e874a3ec)

6.3 Suggested ontology terms (mechanism annotation)

Suggestions (not exhaustively evidenced in the retrieved texts): - GO biological process: steroid biosynthetic process; glucocorticoid biosynthetic process; mineralocorticoid biosynthetic process; androgen biosynthetic process; response to corticotropin. - Cell Ontology (CL): adrenal cortical cell; zona fasciculata cell; zona glomerulosa cell. - UBERON: adrenal gland; adrenal cortex.

7. Anatomical structures affected

Primary: adrenal cortex (site of impaired steroidogenesis and hyperplasia). (concolino2025geneticsincongenital pages 1-2, uslar2023clinicalupdateon pages 3-6)

Secondary / complications: - Gonads/reproductive axis: infertility, menstrual dysfunction; TARTs (testicular adrenal rest tumors) in males. (uslar2023clinicalupdateon pages 9-10) - Cardiometabolic and skeletal systems: obesity, hypertension, dyslipidemia, abnormal glucose homeostasis, osteoporosis/osteopenia. (righi2023longtermcardiometabolicmorbidity pages 1-2, zaric2025metabolicsyndromespectrum pages 12-14)

8. Temporal development

  • SW classic: onset at birth/early infancy with risk of life-threatening salt-wasting crisis if unrecognized. (uslar2023clinicalupdateon pages 3-6, gunes2025clinicalbiochemicaland pages 1-2)
  • SV classic: typically recognized in infancy/childhood via hyperandrogenic signs (accelerated growth, advanced bone age, early pubic hair). (gunes2025clinicalbiochemicaland pages 1-2, uslar2023clinicalupdateon pages 3-6)
  • NCCAH: later onset (childhood/adolescence/adulthood) with hyperandrogenism (acne, hirsutism, menstrual irregularities/infertility). (uslar2023clinicalupdateon pages 3-6, gunes2025clinicalbiochemicaland pages 1-2)

9. Inheritance and population

9.1 Epidemiology (selected recent/representative statistics)

  • Classic CAH frequency (US, literature estimate in claims paper): ~1:16,000 children. (harasymiw2020attentiondeficithyperactivitydisorderamong pages 2-3)
  • Nonclassic CAH prevalence (literature estimate in claims paper): ~1:500. (harasymiw2020attentiondeficithyperactivitydisorderamong pages 2-3)
  • Administrative prevalence in US insured populations (MarketScan/Medicaid, ages 5–18): 10.1 per 100,000 (Commercial) and 7.2 per 100,000 (Medicaid). (harasymiw2020attentiondeficithyperactivitydisorderamong pages 1-2)
  • Newborn screening cohort (North India hospital program; 2008–2017; n=13,376): confirmed CAH birth prevalence ~1:2,500, with sensitivity 100% and specificity 99.9% for the CAH screening protocol using dried-blood-spot 17-OHP. (verma2020newbornscreeningfor pages 3-4, verma2020newbornscreeningfor pages 1-2)

9.2 Inheritance and recurrence

  • Autosomal recessive inheritance is consistently stated for 21-OHD CAH. (concolino2025geneticsincongenital pages 1-2, gunes2025clinicalbiochemicaland pages 1-2)
  • A prenatal diagnosis/screening review notes a 1 in 4 recurrence risk for any child of carrier parents and 1 in 8 risk for an affected female child (reflecting sex-limited virilization concern). (abalı2025antenataldiagnosisand pages 1-2)

9.3 Population genetics

Severe-allele carrier prevalence is summarized as ~2% (1 in 60) in a multidisciplinary review. (uslar2023clinicalupdateon pages 9-10)

10. Diagnostics

Biochemical diagnosis is anchored in 17-hydroxyprogesterone (17-OHP) measurement, assay-aware thresholds, ACTH stimulation testing, and molecular confirmation when indicated.

Test/biomarker Specimen & timing Decision thresholds/cutoffs Interpretation/use Supporting citation
Basal 17-hydroxyprogesterone (17-OHP) by immunoassay (suggested LOINC-style concept: 17-hydroxyprogesterone [Mass/volume] in Serum or Plasma) Fasting blood/plasma, before 9:00 AM; in menstruating women, sample in early follicular phase >2 ng/mL suspicious; >7–10 ng/mL considered diagnostic by consensus in reviewed clinical update First-line biochemical screen for suspected 21-hydroxylase deficiency; values in indeterminate range should prompt ACTH stimulation or additional testing (uslar2023clinicalupdateon pages 3-6)
Basal 17-hydroxyprogesterone (17-OHP) by LC-MS/MS (suggested LOINC-style concept: 17-hydroxyprogesterone [Mass/volume] in Serum or Plasma by LC-MS/MS) Fasting blood/plasma, before 9:00 AM; early follicular phase if cycling >0.8 ng/mL suspicious Preferred analytical method in the 2023 multidisciplinary review because of improved specificity; used as the main basal threshold before confirmatory ACTH stimulation (uslar2023clinicalupdateon pages 3-6, uslar2023clinicalupdateon pages 6-7)
Basal 17-hydroxyprogesterone (17-OHP), conventional diagnostic threshold from 2025 review (suggested LOINC-style concept: 17-hydroxyprogesterone [Mass/volume] in Serum) Early morning blood sample >1000 ng/dL supports diagnosis of 21-OHD High morning basal 17-OHP strongly supports CAH due to 21-hydroxylase deficiency; lower borderline values require ACTH stimulation (gunes2025clinicalbiochemicaland pages 1-2)
Borderline basal 17-hydroxyprogesterone (17-OHP) range requiring ACTH test (suggested LOINC-style concept: 17-hydroxyprogesterone [Mass/volume] in Serum) Early morning blood sample 200–1000 ng/dL = borderline range Borderline basal results should be followed by ACTH stimulation testing to clarify nonclassic or less severe 21-OHD (gunes2025clinicalbiochemicaland pages 1-2)
ACTH stimulation test with 17-OHP readout by LC-MS/MS (suggested LOINC-style concepts: Corticotropin stimulation panel; 17-hydroxyprogesterone [Mass/volume] in Serum or Plasma post stimulation) 250 µg ACTH (i.m. or i.v.); stimulated blood sampling after standard ACTH test Stimulated 17-OHP >3 ng/mL confirms diagnosis in cited LC-MS/MS framework Recommended confirmatory test for intermediate/borderline cases and to assess cortisol response in NCCAH (uslar2023clinicalupdateon pages 3-6, uslar2023clinicalupdateon pages 6-7)
ACTH stimulation test (procedure detail) 250 µg ACTH intramuscular or intravenous Procedure threshold not itself diagnostic; used when basal 17-OHP is indeterminate or ACTH reserve/cortisol response is questioned Confirms CAH/NCCAH in equivocal cases and helps assess adrenal cortisol reserve; genotype testing is recommended when stimulated 17-OHP is nondiagnostic or ACTH testing is unavailable (uslar2023clinicalupdateon pages 6-7)
Genotype testing (CYP21A2) (suggested LOINC-style concept: CYP21A2 gene targeted mutation analysis / full gene analysis) Blood or DNA sample; no timing requirement No numeric cutoff; indicated when biochemical profile is suspicious, ACTH testing is incomplete/unavailable, or for recurrence-risk interpretation Supports molecular confirmation, genotype–phenotype interpretation, parental carrier assessment, and counseling (gunes2025clinicalbiochemicaland pages 1-2, abalı2025antenataldiagnosisand pages 1-2, uslar2023clinicalupdateon pages 6-7)
Newborn screening 17-OHP on dried blood spot, term infant (suggested LOINC-style concept: 17-hydroxyprogesterone [Moles/volume] in Dried blood spot) Newborn dried blood specimen <30 nmol/L normal; 30–90 nmol/L intermediate; >90 nmol/L positive Population screening for severe CAH; intermediate/positive samples in the India cohort were repeated on a separate blood spot before reporting (verma2020newbornscreeningfor pages 1-2, verma2020newbornscreeningfor pages 2-3)
Newborn screening 17-OHP on dried blood spot, preterm infant (suggested LOINC-style concept: 17-hydroxyprogesterone [Moles/volume] in Dried blood spot) Newborn dried blood specimen <60 nmol/L normal; 60–90 nmol/L intermediate; >90 nmol/L positive Adjusted newborn-screening interpretation for prematurity in the India cohort protocol (verma2020newbornscreeningfor pages 1-2, verma2020newbornscreeningfor pages 2-3)
Newborn screening program performance (India cohort) 13,376 newborns screened, dried blood 17-OHP 15 screen-positive, 5 true positive, 10 false positive; false-positive rate 0.07%; PPV 33.3%; NPV 100%; sensitivity 100%; specificity 99.9%; birth prevalence 0.04% (5/13,376) ≈ 1:2,500 Illustrates real-world performance of newborn screening for CAH using 17-OHP in a hospital-based Indian cohort (verma2020newbornscreeningfor pages 1-2, verma2020newbornscreeningfor pages 3-4)
Confirmatory steroid panel after positive newborn screen (suggested LOINC-style concepts: 17-hydroxyprogesterone [Mass/volume] in Serum; Cortisol [Mass/volume] in Serum; Dehydroepiandrosterone [Mass/volume] in Serum) Fresh serum/blood draw after recall; serum cortisol measured at 8 AM and 4 PM in cited cohort No single universal cutoff provided in extracted text Used to confirm abnormal dried-blood-spot screening results after recall of screen-positive newborns (verma2020newbornscreeningfor pages 2-3)

Table: This table summarizes diagnostic tests and cutoffs for congenital adrenal hyperplasia due to 21-hydroxylase deficiency, including basal and stimulated 17-OHP thresholds, assay-specific interpretation, and newborn screening metrics. It is useful as a compact reference for comparing immunoassay, LC-MS/MS, ACTH stimulation, and screening-based approaches.

Key points from a 2023 multidisciplinary program review include: (i) LC–MS/MS is recommended to improve steroid specificity; (ii) basal sampling should be fasting before 9 AM, and for cycling women in the early follicular phase; (iii) ACTH stimulation (250 µg i.m./i.v.) is used to confirm intermediate cases; and (iv) genotype testing is recommended when biochemical evaluation is suspicious or incomplete. (uslar2023clinicalupdateon pages 3-6, uslar2023clinicalupdateon pages 6-7)

Newborn screening implementation (real-world program example): A decade-long North Indian hospital screening program used dried-blood-spot 17-OHP with term/preterm cutoffs, identified 15 screen positives with 5 true positives (PPV 33.3%), and reported sensitivity 100% and specificity 99.9%. (verma2020newbornscreeningfor pages 3-4, verma2020newbornscreeningfor pages 1-2)

11. Outcomes / prognosis

11.1 Cardiometabolic and bone morbidity (recent data)

A 2023 multicentre specialist survey of 244 adults with classic 21-OHD CAH (median age 33 years) found 30% (73/244) were treated for ≥1 of six major comorbidity domains; among treated comorbidities, osteoporosis/osteopenia treatment was most frequent (59%), followed by hyperlipidaemia (23%), type 2 diabetes/hyperinsulinaemia (22%), hypertension (14%), cardiovascular disease (11%), and obesity (4%). (righi2023longtermcardiometabolicmorbidity pages 1-2)

A 2025 pediatric systematic review synthesizing studies through 2024 reports increased cardiometabolic risk factors in children with classic CAH; one included dataset reported 58% systolic hypertension and 24% diastolic hypertension with additional abnormalities in nocturnal dipping and subclinical vascular markers. (zaric2025metabolicsyndromespectrum pages 12-14)

11.2 Autoimmune comorbidity

A Swedish national cohort study (n=714 21-OHD; 71,400 controls) found autoimmune disorders in 7.4% vs 5.1% of controls (RR 1.47, 95% CI 1.13–1.91), with increased autoimmune endocrine and thyroid disorders. (falhammar2019increasedriskof pages 1-2)

12. Treatment

Standard of care focuses on replacing deficient hormones and limiting androgen excess, balanced against harms of chronic supraphysiologic glucocorticoid exposure.

Intervention Mechanism/goal Typical use case Key quantitative data Safety/limitations MAXO term suggestions Citations
Hydrocortisone replacement (children) Replace cortisol deficiency; suppress excess ACTH-driven adrenal androgen production while minimizing hypercortisolism First-line long-term therapy in pediatric classic 21-hydroxylase deficiency Preferred regimen 10–15 mg/m²/day divided every 8 h (uslar2023clinicalupdateon pages 6-7) Conventional dosing does not reproduce physiologic circadian cortisol rhythm; excess exposure is linked to obesity, hypertension, osteoporosis, and adverse cardiometabolic profile (righi2023longtermcardiometabolicmorbidity pages 1-2) MAXO: glucocorticoid replacement therapy; hydrocortisone administration (uslar2023clinicalupdateon pages 6-7, righi2023longtermcardiometabolicmorbidity pages 1-2)
Hydrocortisone replacement (adults) Cortisol replacement with partial androgen control Standard maintenance therapy in adults with classic CAH Suggested regimen 15–25 mg/day, with last dose ≥6 h before bedtime (uslar2023clinicalupdateon pages 6-7) Undertreatment leaves androgen excess uncontrolled; overtreatment increases metabolic and bone morbidity (uslar2023clinicalupdateon pages 6-7, righi2023longtermcardiometabolicmorbidity pages 1-2) MAXO: glucocorticoid replacement therapy; hydrocortisone administration (uslar2023clinicalupdateon pages 6-7, righi2023longtermcardiometabolicmorbidity pages 1-2)
Stress-dose glucocorticoids / sick-day management Prevent adrenal crisis during physiological stress Major illness, surgery, trauma, childbirth; also emphasized as lifelong emergency management in severe CAH Review evidence notes lifelong need for “sick day” dosing in response to stressors (harris2025congenitaladrenalhyperplasia pages 7-9) Required because impaired stress response persists despite routine replacement; inadequate stress dosing risks adrenal crisis (harris2025congenitaladrenalhyperplasia pages 7-9) MAXO: stress-dose steroid therapy; adrenal crisis prophylaxis (harris2025congenitaladrenalhyperplasia pages 7-9)
Neonatal salt-wasting crisis hydrocortisone regimen Emergency glucocorticoid rescue in adrenal crisis / severe SW-CAH Neonates with salt-wasting presentation or adrenal insufficiency Initial hydrocortisone bolus 5 mg/kg, then 25 mg/24 h infusion or divided doses (uslar2023clinicalupdateon pages 6-7) Requires urgent electrolyte/fluid management and specialist care; delay can be life-threatening (gunes2025clinicalbiochemicaland pages 1-2, uslar2023clinicalupdateon pages 6-7) MAXO: emergency hydrocortisone therapy; adrenal crisis treatment (gunes2025clinicalbiochemicaland pages 1-2, uslar2023clinicalupdateon pages 6-7)
Mineralocorticoid replacement (fludrocortisone) Replace aldosterone deficiency; maintain sodium balance and blood pressure Classic salt-wasting CAH; many adults continue combined GC+MC therapy In one adult cohort, 174/244 (71%) received fludrocortisone with glucocorticoids (righi2023longtermcardiometabolicmorbidity pages 2-3) Requires monitoring of plasma renin and electrolytes; annual renin monitoring is recommended with target at the upper normal limit (uslar2023clinicalupdateon pages 6-7, uslar2023clinicalupdateon pages 9-10) MAXO: mineralocorticoid replacement therapy; fludrocortisone administration (uslar2023clinicalupdateon pages 6-7, righi2023longtermcardiometabolicmorbidity pages 2-3, uslar2023clinicalupdateon pages 9-10)
Monitoring during glucocorticoid/mineralocorticoid therapy Optimize replacement and avoid over/undertreatment Routine follow-up in classic and selected nonclassic CAH Recommended monitoring includes plasma renin, electrolytes, cortisol, aldosterone, androstenedione, DHEAS; annual BP and BMI monitoring advised (uslar2023clinicalupdateon pages 6-7, uslar2023clinicalupdateon pages 9-10) Biomarkers vary by assay, timing, age, and medication schedule; standardization remains challenging (uslar2023clinicalupdateon pages 9-10) MAXO: therapeutic drug monitoring; endocrine laboratory monitoring (uslar2023clinicalupdateon pages 6-7, uslar2023clinicalupdateon pages 9-10)
Combined oral contraceptives (OCPs) for NCCAH hyperandrogenism Suppress ovarian androgen production and improve hirsutism/acne/cycle control First-line adjunct in women with NCCAH-related hirsutism/acne Identified as first-line androgen-management option in NCCAH (uslar2023clinicalupdateon pages 9-10) Symptomatic treatment; does not correct underlying adrenal enzyme defect (uslar2023clinicalupdateon pages 9-10) MAXO: oral contraceptive therapy; anti-hyperandrogenism management (uslar2023clinicalupdateon pages 9-10)
Spironolactone adjunct Antiandrogen therapy for persistent hirsutism/acne Add-on when OCPs alone are insufficient in NCCAH Suggested dose 50–100 mg/day (uslar2023clinicalupdateon pages 9-10) Adjunctive/symptomatic rather than disease-modifying; standard antiandrogen precautions apply (uslar2023clinicalupdateon pages 9-10) MAXO: antiandrogen therapy; spironolactone administration (uslar2023clinicalupdateon pages 9-10)
Flutamide adjunct Androgen receptor blockade to improve hyperandrogenic symptoms Alternative add-on antiandrogen in NCCAH Suggested dose 62.5–125 mg/day (uslar2023clinicalupdateon pages 9-10) Adjunctive/symptomatic therapy; use limited by known antiandrogen safety concerns (not detailed in excerpt) (uslar2023clinicalupdateon pages 9-10) MAXO: antiandrogen therapy; flutamide administration (uslar2023clinicalupdateon pages 9-10)
Crinecerfont CRF1 receptor antagonist that lowers ACTH drive, enabling androgen control with lower glucocorticoid doses Emerging adjunct for classic CAH with need to reduce supraphysiologic glucocorticoid exposure Phase 3 adults: glucocorticoid dose change −27.3% vs −10.3% placebo; 62.7% vs 17.5% achieved physiologic GC dose; week-4 androstenedione −299 ng/dL vs +45.5 ng/dL; P<0.001 for primary comparisons (auchus2024phase3trial pages 1-3) Most common adverse events were fatigue and headache; intended as adjunct, not replacement for mandatory steroid therapy (auchus2024phase3trial pages 1-3) MAXO: corticotropin-releasing hormone receptor antagonist therapy; glucocorticoid-sparing therapy (auchus2024phase3trial pages 1-3)
Tildacerfont Investigational CRF1 receptor antagonist to reduce ACTH-driven androgen excess Experimental adjunct in adults/children with CAH Adult Phase 2b trials NCT04457336 and NCT04544410; pediatric Phase 2 NCT05128942; listed statuses were terminated in retrieved ClinicalTrials.gov summaries (NCT04457336 chunk 3) Development status uncertain/limited by trial termination in retrieved records; no phase 3 efficacy data in current evidence set MAXO: corticotropin-releasing hormone receptor antagonist therapy (NCT04457336 chunk 3)
Gene therapy (BBP-631 / gene-transfer approaches) Deliver functional CYP21A2 to restore steroidogenesis Experimental treatment for classic CAH Review notes BBP-631 (AAV5 carrying wild-type CYP21A2) in phase 1/2 and cites preclinical rescue of steroidogenesis in Cyp21-deficient mice/non-human primates; ClinicalTrials.gov lists NCT04783181 as an active-not-recruiting phase 1/2 gene therapy study with planned enrollment 8 (glazova2023modelsofcongenital pages 2-4) Experimental; long-term durability, adrenal targeting, and safety remain under investigation (glazova2023modelsofcongenital pages 2-4) MAXO: gene replacement therapy; adeno-associated viral gene therapy (glazova2023modelsofcongenital pages 2-4)
Ultradian subcutaneous hydrocortisone infusion More physiologic cortisol delivery pattern than conventional oral dosing Experimental/selected use in adrenal insufficiency and CAH Clinical trial NCT02096510 completed; phase 1/2 interventional study with 8 participants in Addison disease and CAH (clinical trial summary) (NCT02096510 chunk 2) Limited evidence base and specialized delivery burden; not routine standard-of-care in retrieved evidence MAXO: continuous subcutaneous hydrocortisone infusion (NCT02096510 chunk 2)

Table: This table summarizes standard, adjunctive, emerging, and experimental interventions for congenital adrenal hyperplasia due to 21-hydroxylase deficiency, with quantitative dosing or trial data where available. It is designed to support rapid comparison of treatment goals, use cases, limitations, and ontology-aligned action terms.

12.1 Standard pharmacotherapy (real-world implementation)

  • Glucocorticoid replacement: hydrocortisone is preferred; one review provides typical dosing ranges (children 10–15 mg/m²/day, adults 15–25 mg/day) and an emergency neonatal regimen (bolus + infusion). (uslar2023clinicalupdateon pages 6-7)
  • Mineralocorticoid replacement: fludrocortisone and monitoring of renin/electrolytes are emphasized for SW-CAH; in one adult cohort, 71% received fludrocortisone. (righi2023longtermcardiometabolicmorbidity pages 2-3, uslar2023clinicalupdateon pages 9-10)
  • Adjunct hyperandrogenism therapy in NCCAH: OCPs as first-line, with antiandrogens (spironolactone, flutamide) as add-ons when needed. (uslar2023clinicalupdateon pages 9-10)

12.2 Recent developments (2023–2024 prioritized)

Crinecerfont (CRF1 receptor antagonist): In a randomized phase 3 trial (NEJM, Aug 2024; ClinicalTrials.gov NCT04490915), crinecerfont enabled clinically meaningful glucocorticoid dose reduction while maintaining androstenedione control: −27.3% dose reduction vs −10.3% placebo (P<0.001), and 62.7% vs 17.5% achieved physiologic glucocorticoid doses. Androstenedione fell by −299 ng/dL at week 4 vs an increase with placebo; fatigue and headache were the most common adverse events. (auchus2024phase3trial pages 1-3)

12.3 Experimental / pipeline approaches

  • Gene therapy: A 2023 model-and-translation review describes an AAV5 gene therapy candidate (BBP-631, CYP21A2) in phase 1/2, and ClinicalTrials.gov lists a CAH gene therapy study NCT04783181 (planned enrollment 8). (glazova2023modelsofcongenital pages 2-4)
  • Physiologic replacement strategies: ultradian subcutaneous hydrocortisone infusion has been studied in a completed phase 1/2 trial including CAH (NCT02096510). (NCT02096510 chunk 2)

13. Prevention

13.1 Primary prevention

Not applicable in the traditional exposure-avoidance sense for a monogenic, autosomal recessive condition.

13.2 Secondary prevention: newborn screening

Multiple reviews advocate newborn screening for early detection of severe forms to reduce mortality and improve management/sex assignment; a large hospital-based India cohort demonstrates feasibility and quantifies performance. (uslar2023clinicalupdateon pages 3-6, abalı2025antenataldiagnosisand pages 1-2, verma2020newbornscreeningfor pages 3-4)

13.3 Genetic counseling / reproductive options

Accurate molecular diagnosis (e.g., CYP21A2 sequencing plus MLPA in certified laboratories) is emphasized for counseling; prenatal diagnosis and management remain technically and ethically complex. (abalı2025antenataldiagnosisand pages 1-2)

14. Other species / natural disease

CAH-like syndromes and enzyme deficiencies have been reported in domestic animals (e.g., cats; dogs), and non-traditional models (ferrets, pigs, spiny mice) are reviewed as potentially useful for adrenal biology due to closer adrenal anatomy/steroidogenesis than rodents. (bilyalova2024nonclassicalanimalmodels pages 2-4)

15. Model organisms

15.1 Zebrafish (in vivo 21-OHD modeling)

A TALEN-generated zebrafish cyp21a2 null model showed reduced cortisol, increased 17-OHP and 21-deoxycortisol, HPI-axis upregulation, and interrenal hyperplasia, supporting use for systemic consequences of glucocorticoid deficiency; the paper cites CAH incidence ~1 in 10,000–1 in 15,000. (eachus2017geneticdisruptionof pages 1-2)

15.2 Mouse models (including humanized CYP21A2)

A 2024 paper reports a viable humanized mouse model carrying the clinically relevant CYP21A2 p.R484Q variant that develops adrenal hyperplasia and steroid abnormalities and displays sex-specific reproductive phenotypes (female infertility). (thirumalasetty2024ahumanizedand pages 1-2)

A 2022 study established a humanized CYP21A2 mouse platform (Cyp21a1 replaced by human CYP21A2) that is phenotypically normal, intended as a base for introducing pathogenic mutations. (schubert2022cyp21a2geneexpression pages 1-2)

15.3 Model limitations (expert analysis)

A review of adrenal genetic disorder models emphasizes that rodent adrenal steroidogenesis differs from humans (e.g., lack of adrenal 17-hydroxylase and androgen production), limiting recapitulation of human virilization/hyperandrogenism phenotypes. (beuschlein2023animalmodelsof pages 2-4)

Direct abstract quotes (selected, for anchoring key claims)

  • Uslar et al. (2023) describe CAH as “characterized by the overproduction of androgen, along with variable degrees of cortisol and aldosterone deficiency.” (uslar2023clinicalupdateon pages 3-6)
  • Auchus et al. (NEJM 2024) conclude: “crinecerfont permitted reduction of supraphysiological glucocorticoid doses, including to physiological range…” (auchus2024phase3trial pages 1-3)
  • Verma et al. (2020) report: “From January 2008 through December 2017, 13,376 newborns were screened… by measuring… 17-hydroxyprogesterone…” and report CAH birth prevalence 1:2,500 with “100% sensitivity and >99% specificity.” (verma2020newbornscreeningfor pages 1-2)

Evidence-backed subtype summary table

CAH subtype / etiology Causal gene(s) Key biochemical hallmarks Typical onset Key reference(s)
21-hydroxylase deficiency, classic salt-wasting (SW) CYP21A2 Cortisol deficiency with aldosterone deficiency; excess adrenal androgens; neonatal salt-wasting crisis with electrolyte disturbance; residual enzyme activity typically <1% (uslar2023clinicalupdateon pages 3-6, uslar2023clinicalupdateon pages 6-7, concolino2025geneticsincongenital pages 1-2) Neonatal / early infancy (uslar2023clinicalupdateon pages 3-6, concolino2025geneticsincongenital pages 1-2) Uslar et al., 2023, J Clin Med, https://doi.org/10.3390/jcm12093128 (uslar2023clinicalupdateon pages 3-6, uslar2023clinicalupdateon pages 6-7); Concolino & Falhammar, 2025, J Endocrine Soc, https://doi.org/10.1210/jendso/bvaf018 (concolino2025geneticsincongenital pages 1-2)
21-hydroxylase deficiency, classic simple virilizing (SV) CYP21A2 Cortisol deficiency with preserved mineralocorticoid function; androgen excess with virilization / precocious pubarche / accelerated growth; residual activity about 1–2% or 1–10% depending on grouping scheme (uslar2023clinicalupdateon pages 3-6, uslar2023clinicalupdateon pages 6-7) Infancy / childhood (gunes2025clinicalbiochemicaland pages 1-2, uslar2023clinicalupdateon pages 3-6) Uslar et al., 2023, J Clin Med, https://doi.org/10.3390/jcm12093128 (uslar2023clinicalupdateon pages 3-6, uslar2023clinicalupdateon pages 6-7); Güneş et al., 2025, JCRPE, https://doi.org/10.4274/jcrpe.galenos.2024.2024-6-6-s (gunes2025clinicalbiochemicaland pages 1-2)
21-hydroxylase deficiency, nonclassic (NCCAH) CYP21A2 Mild cortisol impairment with hyperandrogenism; morning 17-OHP often elevated, ACTH-stimulated increase used diagnostically; residual activity about 20–50% (or 20–60% in mutation grouping) (uslar2023clinicalupdateon pages 3-6, uslar2023clinicalupdateon pages 6-7) Late childhood, adolescence, or adulthood (gunes2025clinicalbiochemicaland pages 1-2, uslar2023clinicalupdateon pages 3-6) Uslar et al., 2023, J Clin Med, https://doi.org/10.3390/jcm12093128 (uslar2023clinicalupdateon pages 3-6, uslar2023clinicalupdateon pages 6-7); Güneş et al., 2025, JCRPE, https://doi.org/10.4274/jcrpe.galenos.2024.2024-6-6-s (gunes2025clinicalbiochemicaland pages 1-2)
11β-hydroxylase deficiency CYP11B1 Inability to produce cortisol and aldosterone with excessive adrenal androgen production; laboratory/clinical features can resemble 21-OHD but mineralocorticoid deficiency findings are not observed (OpenTargets Search: Congenital adrenal hyperplasia) Childhood / early life (not further specified in extracted evidence) (OpenTargets Search: Congenital adrenal hyperplasia) İsakoca et al., 2025, JCRPE, https://doi.org/10.4274/jcrpe.galenos.2024.2024-6-21-s (OpenTargets Search: Congenital adrenal hyperplasia)
17α-hydroxylase deficiency CYP17A1 Impaired sex steroid synthesis; 46,XY DSD in boys and estrogen deficiency with immature puberty / primary amenorrhea in girls (OpenTargets Search: Congenital adrenal hyperplasia) Childhood to adolescence / puberty (OpenTargets Search: Congenital adrenal hyperplasia) İsakoca et al., 2025, JCRPE, https://doi.org/10.4274/jcrpe.galenos.2024.2024-6-21-s (OpenTargets Search: Congenital adrenal hyperplasia)
3β-hydroxysteroid dehydrogenase deficiency HSD3B2 Early impairment of adrenal and gonadal steroid biosynthesis; inadequate virilization in boys, variable virilization in girls; may present with salt-wasting crisis (OpenTargets Search: Congenital adrenal hyperplasia) Neonatal / infancy, sometimes delayed puberty (OpenTargets Search: Congenital adrenal hyperplasia) İsakoca et al., 2025, JCRPE, https://doi.org/10.4274/jcrpe.galenos.2024.2024-6-21-s (OpenTargets Search: Congenital adrenal hyperplasia)
Lipoid CAH STAR Near-complete deficiency of adrenal and gonadal steroid hormones with progressive accumulation of cholesterol esters in adrenal gland; severe salt wasting (OpenTargets Search: Congenital adrenal hyperplasia) First year of life (OpenTargets Search: Congenital adrenal hyperplasia) İsakoca et al., 2025, JCRPE, https://doi.org/10.4274/jcrpe.galenos.2024.2024-6-21-s (OpenTargets Search: Congenital adrenal hyperplasia)

Table: This table compacts the main congenital adrenal hyperplasia etiologies discussed in the gathered evidence, linking each subtype to its causal gene, core biochemical pattern, and typical onset. It is useful as a quick-reference map for differentiating common 21-hydroxylase deficiency forms from rarer enzyme defects.

Notes on evidence gaps for this run

  • Specific OMIM, Orphanet (ORPHA), MeSH, and ICD-11 identifiers were not retrieved as full-text evidence in this tool run; the report therefore does not assert them.
  • Detailed ClinVar-style variant lists (HGVS nomenclature, allele frequencies in gnomAD) and epigenetic studies were not present in retrieved evidence and are not enumerated.

Key source URLs (with publication dates)

  • Uslar T et al. Journal of Clinical Medicine 2023-04. https://doi.org/10.3390/jcm12093128 (uslar2023clinicalupdateon pages 3-6)
  • Auchus RJ et al. New England Journal of Medicine 2024-08. https://doi.org/10.1056/NEJMoa2404656 (auchus2024phase3trial pages 1-3)
  • Concolino P, Falhammar H. Journal of the Endocrine Society 2025-01. https://doi.org/10.1210/jendso/bvaf018 (concolino2025geneticsincongenital pages 1-2)
  • Righi B et al. Endocrine 2023-03. https://doi.org/10.1007/s12020-023-03330-w (righi2023longtermcardiometabolicmorbidity pages 1-2)
  • Verma J et al. Journal of Pediatric Intensive Care 2020-10. https://doi.org/10.1055/s-0039-1698424 (verma2020newbornscreeningfor pages 1-2)

References

  1. (concolino2025geneticsincongenital pages 1-2): Paola Concolino and Henrik Falhammar. Genetics in congenital adrenal hyperplasia due to 21-hydroxylase deficiency and clinical implications. Journal of the Endocrine Society, Jan 2025. URL: https://doi.org/10.1210/jendso/bvaf018, doi:10.1210/jendso/bvaf018. This article has 7 citations and is from a peer-reviewed journal.

  2. (gunes2025clinicalbiochemicaland pages 1-2): Sevinç Odabaşı Güneş, Havva Nur Peltek Kendirci, Edip Ünal, Ayşe Derya Buluş, İsmail Dündar, and Zeynep Şıklar. Clinical, biochemical and molecular characteristics of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Journal of Clinical Research in Pediatric Endocrinology, 17:3-11, Dec 2025. URL: https://doi.org/10.4274/jcrpe.galenos.2024.2024-6-6-s, doi:10.4274/jcrpe.galenos.2024.2024-6-6-s. This article has 16 citations.

  3. (uslar2023clinicalupdateon pages 3-6): Thomas Uslar, Roberto Olmos, Alejandro Martínez-Aguayo, and René Baudrand. Clinical update on congenital adrenal hyperplasia: recommendations from a multidisciplinary adrenal program. Journal of Clinical Medicine, 12:3128, Apr 2023. URL: https://doi.org/10.3390/jcm12093128, doi:10.3390/jcm12093128. This article has 43 citations.

  4. (OpenTargets Search: Congenital adrenal hyperplasia): Open Targets Query (Congenital adrenal hyperplasia, 24 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

  5. (harasymiw2020attentiondeficithyperactivitydisorderamong pages 3-3): Lauren A Harasymiw, Scott D Grosse, and Kyriakie Sarafoglou. Attention-deficit/hyperactivity disorder among us children and adolescents with congenital adrenal hyperplasia. Journal of the Endocrine Society, Oct 2020. URL: https://doi.org/10.1210/jendso/bvaa152, doi:10.1210/jendso/bvaa152. This article has 9 citations and is from a peer-reviewed journal.

  6. (falhammar2019increasedriskof pages 2-3): Henrik Falhammar, Louise Frisén, Angelica Linden Hirschberg, Agneta Nordenskjöld, Catarina Almqvist, and Anna Nordenström. Increased risk of autoimmune disorders in 21-hydroxylase deficiency: a swedish population-based national cohort study. Journal of the Endocrine Society, 3:1039-1052, Apr 2019. URL: https://doi.org/10.1210/js.2019-00122, doi:10.1210/js.2019-00122. This article has 26 citations and is from a peer-reviewed journal.

  7. (auchus2024phase3trial pages 1-3): Richard J. Auchus, Oksana Hamidi, Rosario Pivonello, Irina Bancos, Gianni Russo, Selma F. Witchel, Andrea M. Isidori, Patrice Rodien, Umasuthan Srirangalingam, Florian W. Kiefer, Henrik Falhammar, Deborah P. Merke, Nicole Reisch, Kyriakie Sarafoglou, Gordon B. Cutler, Julia Sturgeon, Eiry Roberts, Vivian H. Lin, Jean L. Chan, and Robert H. Farber. Phase 3 trial of crinecerfont in adult congenital adrenal hyperplasia. New England Journal of Medicine, 391:504-514, Aug 2024. URL: https://doi.org/10.1056/nejmoa2404656, doi:10.1056/nejmoa2404656. This article has 63 citations and is from a highest quality peer-reviewed journal.

  8. (falhammar2019increasedriskof pages 1-2): Henrik Falhammar, Louise Frisén, Angelica Linden Hirschberg, Agneta Nordenskjöld, Catarina Almqvist, and Anna Nordenström. Increased risk of autoimmune disorders in 21-hydroxylase deficiency: a swedish population-based national cohort study. Journal of the Endocrine Society, 3:1039-1052, Apr 2019. URL: https://doi.org/10.1210/js.2019-00122, doi:10.1210/js.2019-00122. This article has 26 citations and is from a peer-reviewed journal.

  9. (righi2023longtermcardiometabolicmorbidity pages 1-2): Beatrice Righi, Salma R. Ali, Jillian Bryce, Jeremy W. Tomlinson, Walter Bonfig, Federico Baronio, Eduardo C. Costa, Guilherme Guaragna-Filho, Guy T’Sjoen, Martine Cools, Renata Markosyan, Tania A. S. S. Bachega, Mirela C. Miranda, Violeta Iotova, Henrik Falhammar, Filippo Ceccato, Marianna R. Stancampiano, Gianni Russo, Eleni Daniel, Richard J. Auchus, Richard J. Ross, and S. Faisal Ahmed. Long-term cardiometabolic morbidity in young adults with classic 21-hydroxylase deficiency congenital adrenal hyperplasia. Endocrine, 80:630-638, Mar 2023. URL: https://doi.org/10.1007/s12020-023-03330-w, doi:10.1007/s12020-023-03330-w. This article has 14 citations and is from a peer-reviewed journal.

  10. (verma2020newbornscreeningfor pages 1-2): Jyotsna Verma, Papai Roy, Divya C. Thomas, Geetu Jhingan, Azad Singh, Sunita Bijarnia-Mahay, and Ishwar C. Verma. Newborn screening for congenital hypothyroidism, congenital adrenal hyperplasia, and glucose-6-phosphate dehydrogenase deficiency for improving health care in india. Journal of Pediatric Intensive Care, 09:040-044, Oct 2020. URL: https://doi.org/10.1055/s-0039-1698424, doi:10.1055/s-0039-1698424. This article has 19 citations.

  11. (eachus2017geneticdisruptionof pages 1-2): Helen Eachus, Andreas Zaucker, James A Oakes, Aliesha Griffin, Meltem Weger, Tülay Güran, Angela Taylor, Abigail Harris, Andy Greenfield, Jonathan L Quanson, Karl-Heinz Storbeck, Vincent T Cunliffe, Ferenc Müller, and Nils Krone. Genetic disruption of 21-hydroxylase in zebrafish causes interrenal hyperplasia. Endocrinology, 158:4165-4173, Sep 2017. URL: https://doi.org/10.1210/en.2017-00549, doi:10.1210/en.2017-00549. This article has 36 citations and is from a domain leading peer-reviewed journal.

  12. (thirumalasetty2024ahumanizedand pages 1-2): Shamini Ramkumar Thirumalasetty, Tina Schubert, Ronald Naumann, Ilka Reichardt, Marie-Luise Rohm, Dana Landgraf, Florian Gembardt, Mirko Peitzsch, Michaela F. Hartmann, Mihail Sarov, Stefan A. Wudy, Nicole Reisch, Angela Huebner, and Katrin Koehler. A humanized and viable animal model for congenital adrenal hyperplasia–cyp21a2-r484q mutant mouse. International Journal of Molecular Sciences, 25:5062, May 2024. URL: https://doi.org/10.3390/ijms25105062, doi:10.3390/ijms25105062. This article has 5 citations.

  13. (glazova2023modelsofcongenital pages 2-4): Olga Glazova, Asya Bastrich, Andrei Deviatkin, Nikita Onyanov, Samira Kaziakhmedova, Liudmila Shevkova, Nawar Sakr, Daria Petrova, Maria V. Vorontsova, and Pavel Volchkov. Models of congenital adrenal hyperplasia for gene therapies testing. International Journal of Molecular Sciences, 24:5365, Mar 2023. URL: https://doi.org/10.3390/ijms24065365, doi:10.3390/ijms24065365. This article has 10 citations.

  14. (uslar2023clinicalupdateon pages 6-7): Thomas Uslar, Roberto Olmos, Alejandro Martínez-Aguayo, and René Baudrand. Clinical update on congenital adrenal hyperplasia: recommendations from a multidisciplinary adrenal program. Journal of Clinical Medicine, 12:3128, Apr 2023. URL: https://doi.org/10.3390/jcm12093128, doi:10.3390/jcm12093128. This article has 43 citations.

  15. (uslar2023clinicalupdateon pages 9-10): Thomas Uslar, Roberto Olmos, Alejandro Martínez-Aguayo, and René Baudrand. Clinical update on congenital adrenal hyperplasia: recommendations from a multidisciplinary adrenal program. Journal of Clinical Medicine, 12:3128, Apr 2023. URL: https://doi.org/10.3390/jcm12093128, doi:10.3390/jcm12093128. This article has 43 citations.

  16. (abalı2025antenataldiagnosisand pages 1-2): Zehra Yavaş Abalı, Erdal Kurnaz, and Tülay Güran. Antenatal diagnosis and treatment in congenital adrenal hyperplasia due to 21-hydroxylase deficiency and congenital adrenal hyperplasia screening in newborns. Journal of Clinical Research in Pediatric Endocrinology, 17:33-43, Dec 2025. URL: https://doi.org/10.4274/jcrpe.galenos.2024.2024-6-10-s, doi:10.4274/jcrpe.galenos.2024.2024-6-10-s. This article has 1 citations.

  17. (righi2023longtermcardiometabolicmorbidity pages 4-5): Beatrice Righi, Salma R. Ali, Jillian Bryce, Jeremy W. Tomlinson, Walter Bonfig, Federico Baronio, Eduardo C. Costa, Guilherme Guaragna-Filho, Guy T’Sjoen, Martine Cools, Renata Markosyan, Tania A. S. S. Bachega, Mirela C. Miranda, Violeta Iotova, Henrik Falhammar, Filippo Ceccato, Marianna R. Stancampiano, Gianni Russo, Eleni Daniel, Richard J. Auchus, Richard J. Ross, and S. Faisal Ahmed. Long-term cardiometabolic morbidity in young adults with classic 21-hydroxylase deficiency congenital adrenal hyperplasia. Endocrine, 80:630-638, Mar 2023. URL: https://doi.org/10.1007/s12020-023-03330-w, doi:10.1007/s12020-023-03330-w. This article has 14 citations and is from a peer-reviewed journal.

  18. (righi2023longtermcardiometabolicmorbidity pages 2-3): Beatrice Righi, Salma R. Ali, Jillian Bryce, Jeremy W. Tomlinson, Walter Bonfig, Federico Baronio, Eduardo C. Costa, Guilherme Guaragna-Filho, Guy T’Sjoen, Martine Cools, Renata Markosyan, Tania A. S. S. Bachega, Mirela C. Miranda, Violeta Iotova, Henrik Falhammar, Filippo Ceccato, Marianna R. Stancampiano, Gianni Russo, Eleni Daniel, Richard J. Auchus, Richard J. Ross, and S. Faisal Ahmed. Long-term cardiometabolic morbidity in young adults with classic 21-hydroxylase deficiency congenital adrenal hyperplasia. Endocrine, 80:630-638, Mar 2023. URL: https://doi.org/10.1007/s12020-023-03330-w, doi:10.1007/s12020-023-03330-w. This article has 14 citations and is from a peer-reviewed journal.

  19. (zaric2025metabolicsyndromespectrum pages 1-2): Sanja Panic Zaric, Tatjana Milenkovic, Sladjana Todorovic, Katarina Mitrovic, Dimitrije Cvetkovic, Maja Cehic, Jelena Vekic, Katja Dumic, and Rade Vukovic. Metabolic syndrome spectrum in children with classic congenital adrenal hyperplasia—a comprehensive review. Metabolites, 15:89, Feb 2025. URL: https://doi.org/10.3390/metabo15020089, doi:10.3390/metabo15020089. This article has 4 citations.

  20. (zaric2025metabolicsyndromespectrum pages 12-14): Sanja Panic Zaric, Tatjana Milenkovic, Sladjana Todorovic, Katarina Mitrovic, Dimitrije Cvetkovic, Maja Cehic, Jelena Vekic, Katja Dumic, and Rade Vukovic. Metabolic syndrome spectrum in children with classic congenital adrenal hyperplasia—a comprehensive review. Metabolites, 15:89, Feb 2025. URL: https://doi.org/10.3390/metabo15020089, doi:10.3390/metabo15020089. This article has 4 citations.

  21. (harris2025congenitaladrenalhyperplasia pages 7-9): David E. Harris. Congenital adrenal hyperplasia: a clinical review. Universal Library of Clinical Nursing, 02:08-17, Feb 2025. URL: https://doi.org/10.70315/uloap.ulcnu.2025.0201002, doi:10.70315/uloap.ulcnu.2025.0201002. This article has 1 citations.

  22. (concolino2025geneticsincongenital media e874a3ec): Paola Concolino and Henrik Falhammar. Genetics in congenital adrenal hyperplasia due to 21-hydroxylase deficiency and clinical implications. Journal of the Endocrine Society, Jan 2025. URL: https://doi.org/10.1210/jendso/bvaf018, doi:10.1210/jendso/bvaf018. This article has 7 citations and is from a peer-reviewed journal.

  23. (harasymiw2020attentiondeficithyperactivitydisorderamong pages 2-3): Lauren A Harasymiw, Scott D Grosse, and Kyriakie Sarafoglou. Attention-deficit/hyperactivity disorder among us children and adolescents with congenital adrenal hyperplasia. Journal of the Endocrine Society, Oct 2020. URL: https://doi.org/10.1210/jendso/bvaa152, doi:10.1210/jendso/bvaa152. This article has 9 citations and is from a peer-reviewed journal.

  24. (harasymiw2020attentiondeficithyperactivitydisorderamong pages 1-2): Lauren A Harasymiw, Scott D Grosse, and Kyriakie Sarafoglou. Attention-deficit/hyperactivity disorder among us children and adolescents with congenital adrenal hyperplasia. Journal of the Endocrine Society, Oct 2020. URL: https://doi.org/10.1210/jendso/bvaa152, doi:10.1210/jendso/bvaa152. This article has 9 citations and is from a peer-reviewed journal.

  25. (verma2020newbornscreeningfor pages 3-4): Jyotsna Verma, Papai Roy, Divya C. Thomas, Geetu Jhingan, Azad Singh, Sunita Bijarnia-Mahay, and Ishwar C. Verma. Newborn screening for congenital hypothyroidism, congenital adrenal hyperplasia, and glucose-6-phosphate dehydrogenase deficiency for improving health care in india. Journal of Pediatric Intensive Care, 09:040-044, Oct 2020. URL: https://doi.org/10.1055/s-0039-1698424, doi:10.1055/s-0039-1698424. This article has 19 citations.

  26. (verma2020newbornscreeningfor pages 2-3): Jyotsna Verma, Papai Roy, Divya C. Thomas, Geetu Jhingan, Azad Singh, Sunita Bijarnia-Mahay, and Ishwar C. Verma. Newborn screening for congenital hypothyroidism, congenital adrenal hyperplasia, and glucose-6-phosphate dehydrogenase deficiency for improving health care in india. Journal of Pediatric Intensive Care, 09:040-044, Oct 2020. URL: https://doi.org/10.1055/s-0039-1698424, doi:10.1055/s-0039-1698424. This article has 19 citations.

  27. (NCT04457336 chunk 3): A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH. Spruce Biosciences. 2020. ClinicalTrials.gov Identifier: NCT04457336

  28. (NCT02096510 chunk 2): Ultradian Subcutaneous Hydrocortisone Infusion in Addison Disease and Congenital Adrenal Hyperplasia. Haukeland University Hospital. 2014. ClinicalTrials.gov Identifier: NCT02096510

  29. (bilyalova2024nonclassicalanimalmodels pages 2-4): Alina Bilyalova, Airat Bilyalov, Nikita Filatov, Elena Shagimardanova, Andrey Kiyasov, Maria Vorontsova, and Oleg Gusev. Non-classical animal models for studying adrenal diseases: advantages, limitations, and implications for research. Laboratory Animal Research, Jun 2024. URL: https://doi.org/10.1186/s42826-024-00212-8, doi:10.1186/s42826-024-00212-8. This article has 4 citations.

  30. (schubert2022cyp21a2geneexpression pages 1-2): Tina Schubert, Nicole Reisch, Ronald Naumann, Ilka Reichardt, Dana Landgraf, Friederike Quitter, Shamini Ramkumar Thirumalasetty, Anne-Kristin Heninger, Mihail Sarov, Mirko Peitzsch, Angela Huebner, and Katrin Koehler. Cyp21a2 gene expression in a humanized 21-hydroxylase mouse model does not affect adrenocortical morphology and function. Journal of the Endocrine Society, Apr 2022. URL: https://doi.org/10.1210/jendso/bvac062, doi:10.1210/jendso/bvac062. This article has 8 citations and is from a peer-reviewed journal.

  31. (beuschlein2023animalmodelsof pages 2-4): Felix Beuschlein. Animal models of adrenal genetic disorders. ArXiv, pages 323-329, Jan 2023. URL: https://doi.org/10.1016/b978-0-12-416006-4.00026-0, doi:10.1016/b978-0-12-416006-4.00026-0. This article has 2 citations.